


**CUMULATIVE
SUPPLEMENT 06
June 2010**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

Cumulative Supplement 06

June 2010

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vii
1.6 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

**CUMULATIVE SUPPLEMENT 06
June 2010**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ASCENT PEDIATRICS INC (ASCENT PEDS)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
GOLDLINE LABORATORIES INC (GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
HLR TECHNOLOGY (HLR)	HOFFMANN LA ROCHE INC (HOFFMANN LA ROCHE)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
KALI LABORATORIES INC (KALI LABS)	PAR PHARMACEUTICAL INC (PAR PHARM)
KALI LABS INC (KALI LABS)	PAR PHARMACEUTICAL INC (PAR PHARM)

MEDICIS PHARMACEUTICAL CORP (MEDICIS)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
MINRAD INC (MINRAD)	PIRAMAL CRITICAL CARE INC (PIRAMAL CRITICAL)
MORTON GROVE ACQUISITION CORP (MORTON GROVE)	WOCKHARDT EU OPERATIONS (SWISS)AG (WOCKHARDT)
MORTON GROVE PHARMACEUTICALS (MORTON GROVE)	WOCKHARDT EU OPERATIONS (SWISS)AG (WOCKHARDT)
MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE PHARMS)	WOCKHARDT EU OPERATIONS (SWISS)AG (WOCKHARDT)
PROCTER AND GAMBLE CO (PROCTER AND GAMBLE)	WARNER CHILCOTT CO LLC (WARNER CHILCOTT)
PROCTER AND GAMBLE CO PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO (PROCTER AND GAMBLE)	WARNER CHILCOTT CO LLC (WARNER CHILCOTT)
SCIELE PHARMA INC (SCIELE PHARMA INC)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE LABORATORIES INC (ZENITH GOLDLINE) ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2009	MAR 2010	JUN 2010	SEPT 2010	DEC 2010
DRUG PRODUCTS LISTED	13065	13216	13445		
SINGLE SOURCE	2460 (18.8%)	2474 (18.7%)	2466 (18.3%)		
MULTISOURCE	10516 (80.5%)	10653 (80.6%)	10890 (81.0%)		

THERAPEUTICALLY EQUIVALENT	10367 (79.3%)	10502 (79.5%)	10732 (79.8%)
NOT THERAPEUTICALLY EQUIVALENT	149 (1.1%)	151 (1.1%)	158 (1.2%)
EXCEPTIONS ¹	89 (0.7%)	89 (0.7%)	89 (0.7%)
NEW MOLECULAR ENTITIES APPROVED	3	5	1
NUMBER OF APPLICANTS	718	727	729

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 30TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

>D>	AB	COBALT LABS INC	25MG	A077532	001	May 07, 2008	Jun	CAHN
>D>	AB		50MG	A077532	002	May 07, 2008	Jun	CAHN
>D>	AB		100MG	A077532	003	May 07, 2008	Jun	CAHN
>A>	AB	WATSON LABS	25MG	A077532	001	May 07, 2008	Jun	CAHN
>A>	AB		50MG	A077532	002	May 07, 2008	Jun	CAHN
>A>	AB		100MG	A077532	003	May 07, 2008	Jun	CAHN

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

@ MIKART 150MG;180MG;30MG

A081096 001 Oct 26, 1990 May DISC

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AA	MIKART	325MG;50MG	A089987	001	Oct 26, 1992	Feb	CTEC
AA	+ VALEANT	325MG;50MG	A087811	001	Jun 19, 1985	Feb	CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ NEXGEN PHARMA 300MG;50MG;40MG

A040885 001 Nov 16, 2009 Feb CRLD

AA WEST WARD 500MG;50MG;40MG

A040261 001 Oct 28, 1998 Feb CTEC

ESGIC-PLUS

AA + MIKART 500MG;50MG;40MG

A040085 001 Mar 28, 1996 Feb CTEC

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA CONCORD LABS NJ 325MG;50MG;40MG

A040864 001 Dec 01, 2008 Feb CTEC

AA 500MG;50MG;40MG

A040883 001 Dec 23, 2008 Feb CTEC

AA MALLINCKRODT 325MG;50MG;40MG

A087804 001 Jan 24, 1985 Feb CTEC

AA MIKART 325MG;50MG;40MG

A089175 001 Jan 21, 1987 Feb CTEC

AA VINTAGE PHARMS 325MG;50MG;40MG

A040511 001 Aug 27, 2003 Feb CTEC

AA 500MG;50MG;40MG

A040513 001 Aug 25, 2003 Feb CTEC

AA WATSON LABS 500MG;50MG;40MG

A040267 001 Jul 30, 1998 Feb CTEC

AA WEST WARD 325MG;50MG;40MG

A089718 001 Jun 12, 1995 Feb CTEC

AA 500MG;50MG;40MG

A040336 001 Aug 18, 1999 Feb CTEC

ESGIC-PLUS

AA + MIKART 500MG;50MG;40MG

A089451 001 May 23, 1988 Feb CTEC

FIORICET

AA + WATSON PHARMS 325MG;50MG;40MG

A088616 001 Nov 09, 1984 Feb CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

+ MIKART 300MG/15ML;10MG/15ML

A040881 001 Feb 25, 2010 Feb NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MIKART 325MG;2.5MG

A040846 001 Jun 09, 2010 May NEWA

650MG;5MG

A040849 001 Jun 09, 2010 May NEWA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

AB + WATSON LABS	650MG;EQ 25MG BASE	A074699 001 Mar 24, 2000 Feb CRLD
TALACEN		
@ SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458 001 Sep 23, 1982 Feb DISC

ACITRETN

CAPSULE; ORAL

SORIATANE

STIEFEL LABS INC	17.5MG	N019821 003 Aug 06, 2009 Jan NEWA
	22.5MG	N019821 004 Aug 06, 2009 Jan NEWA

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ IVAX SUB TEVA PHARMS	200MG	A074674 001 Apr 22, 1997 Apr DISC
AB MYLAN	200MG	A074727 001 Apr 22, 1997 Mar CMFD

TABLET; ORAL

ACYCLOVIR

@ IVAX SUB TEVA PHARMS	400MG	A074836 001 Apr 22, 1997 Apr DISC
@	800MG	A074836 002 Apr 22, 1997 Apr DISC

AB MYLAN	400MG	A075211 001 Sep 28, 1998 Mar CMFD
----------	-------	-----------------------------------

AB	800MG	A075211 002 Sep 28, 1998 Mar CMFD
----	-------	-----------------------------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

>A> AB NYCOMED US	0.1%	A090824 001 Jun 30, 2010 Jun NEWA
-------------------	------	-----------------------------------

DIFFERIN

>D> + GALDERMA LABS LP	0.1%	N020748 001 May 26, 2000 Jun CFTG
------------------------	------	-----------------------------------

>A> AB +	0.1%	N020748 001 May 26, 2000 Jun CFTG
----------	------	-----------------------------------

GEL; TOPICAL

ADAPADENE

>A> AB GLENMARK GENERICS	0.1%	A091314 001 Jul 01, 2010 Jun NEWA
--------------------------	------	-----------------------------------

ADAPALENE

AB PLIVA HRVATSKA DOO	0.1%	A090962 001 Jun 02, 2010 May NEWA
-----------------------	------	-----------------------------------

DIFFERIN

AB + GALDERMA LABS LP	0.1%	N020380 001 May 31, 1996 May CFTG
-----------------------	------	-----------------------------------

LOTION; TOPICAL

DIFFERIN

+ GALDERMA R AND D	0.1%	N022502 001 Mar 17, 2010 Mar NEWA
--------------------	------	-----------------------------------

ALBENDAZOLE

TABLET; ORAL

ALBENZA

>D> + GLAXOSMITHKLINE	200MG	N020666 001 Jun 11, 1996 Jun CAHN
-----------------------	-------	-----------------------------------

>A> + GLAXOSMITHKLINE LLC	200MG	N020666 001 Jun 11, 1996 Jun CAHN
---------------------------	-------	-----------------------------------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN APOTEX INC	EQ 0.021% BASE	A078623 001 Apr 05, 2010 Mar NEWA
AN	EQ 0.042% BASE	A078623 002 Apr 05, 2010 Mar NEWA
AN NEPHRON	EQ 0.021% BASE	A076355 002 Mar 31, 2010 Mar NEWA

SYRUP; ORAL

ALBUTEROL SULFATE

AA AMNEAL PHARMS EQ 2MG BASE/5ML A079241 001 May 12, 2010 May NEWA

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

AB + NYCOMED US 0.05% N018707 001 Dec 14, 1982 May CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	CADISTA PHARMS	EQ 5MG BASE	A090557 001	Feb 18, 2010	Jan	NEWA
AB		EQ 10MG BASE	A090557 002	Feb 18, 2010	Jan	NEWA
AB		EQ 35MG BASE	A090557 003	Feb 18, 2010	Jan	NEWA
AB		EQ 70MG BASE	A090557 004	Feb 18, 2010	Jan	NEWA
>D>	AB COBALT LABS INC	EQ 35MG BASE	A076984 001	Aug 04, 2008	Jun	CAHN
>D>	AB	EQ 40MG BASE	A076984 002	Aug 04, 2008	Jun	CAHN
>D>	AB	EQ 70MG BASE	A076984 003	Aug 04, 2008	Jun	CAHN
>D>	AB SUN PHARM IND	EQ 5MG BASE	A090022 001	Sep 10, 2008	Jun	CAHN
>D>	AB	EQ 10MG BASE	A090022 002	Sep 10, 2008	Jun	CAHN
>D>	AB	EQ 35MG BASE	A090022 003	Sep 10, 2008	Jun	CAHN
>D>	AB	EQ 70MG BASE	A090022 004	Sep 10, 2008	Jun	CAHN
>A>	AB SUN PHARMA GLOBAL	EQ 5MG BASE	A090022 001	Sep 10, 2008	Jun	CAHN
>A>	AB	EQ 10MG BASE	A090022 002	Sep 10, 2008	Jun	CAHN
>A>	AB	EQ 35MG BASE	A090022 003	Sep 10, 2008	Jun	CAHN
>A>	AB	EQ 70MG BASE	A090022 004	Sep 10, 2008	Jun	CAHN
>A>	AB WATSON LABS	EQ 35MG BASE	A076984 001	Aug 04, 2008	Jun	CAHN
>A>	AB	EQ 40MG BASE	A076984 002	Aug 04, 2008	Jun	CAHN
>A>	AB	EQ 70MG BASE	A076984 003	Aug 04, 2008	Jun	CAHN

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	SUN PHARMA GLOBAL	0.25MG	A090082 001	Jun 17, 2010	May	NEWA
AB		0.5MG	A090082 002	Jun 17, 2010	May	NEWA
AB		1MG	A090082 003	Jun 17, 2010	May	NEWA
AB		2MG	A090082 004	Jun 17, 2010	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	WATSON LABS FLORIDA	0.5MG	A077198 001	May 13, 2010	May	NEWA
AB		1MG	A077198 002	May 13, 2010	May	NEWA
AB		2MG	A077198 003	May 13, 2010	May	NEWA
AB		3MG	A077198 004	May 13, 2010	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A078561 001	Mar 16, 2010	Feb	NEWA
AB		0.5MG	A078561 002	Mar 16, 2010	Feb	NEWA
AB		1MG	A078561 003	Mar 16, 2010	Feb	NEWA
AB		2MG	A078561 004	Mar 16, 2010	Feb	NEWA

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

+ USL PHARMA 100MG A076186 001 Dec 16, 2002 May CRLD

TABLET; ORAL

SYMMETREL

@ ENDO PHARMS

100MG

N018101 001

May DISC

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

>D>	AP	SUN PHARM IND'S	500MG/VIAL	A077126 001	Mar 14, 2008	Jun	CAHN
>A>	AP	SUN PHARMA GLOBAL	500MG/VIAL	A077126 001	Mar 14, 2008	Jun	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>D>	AP	+ APOTEX INC	50MG/ML	A076394 001	Apr 25, 2003	Jun	CAHN
>A>	AP	+ CLARIS LIFESCIENCES	50MG/ML	A076394 001	Apr 25, 2003	Jun	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB	COBALT	EQ 2.5MG BASE	A077671 001	Jul 19, 2007	Jun	CAHN
>D>	AB		EQ 5MG BASE	A077671 002	Jul 19, 2007	Jun	CAHN
>D>	AB		EQ 10MG BASE	A077671 003	Jul 19, 2007	Jun	CAHN
	AB	VINTAGE	EQ 2.5MG BASE	A078414 001	Apr 07, 2010	Mar	NEWA
	AB		EQ 5MG BASE	A078414 002	Apr 07, 2010	Mar	NEWA
	AB		EQ 10MG BASE	A078414 003	Apr 07, 2010	Mar	NEWA
>A>	AB	WATSON LABS	EQ 2.5MG BASE	A077671 001	Jul 19, 2007	Jun	CAHN
>A>	AB		EQ 5MG BASE	A077671 002	Jul 19, 2007	Jun	CAHN
>A>	AB		EQ 10MG BASE	A077671 003	Jul 19, 2007	Jun	CAHN
	AB	WORLD GEN	EQ 2.5MG BASE	A077516 001	Jul 11, 2007	Mar	CAHN
	AB		EQ 5MG BASE	A077516 002	Jul 11, 2007	Mar	CAHN
	AB		EQ 10MG BASE	A077516 003	Jul 11, 2007	Mar	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183 001	Apr 15, 2010	Mar	NEWA
AB		EQ 5MG BASE;10MG	A077183 002	Apr 15, 2010	Mar	NEWA
AB		EQ 5MG BASE;20MG	A077183 003	Apr 15, 2010	Mar	NEWA
AB		EQ 10MG BASE;20MG	A077183 004	Apr 15, 2010	Mar	NEWA
AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466 001	Feb 05, 2010	Jan	NEWA
AB		EQ 5MG BASE;10MG	A078466 002	Feb 05, 2010	Jan	NEWA
AB		EQ 5MG BASE;20MG	A078466 003	Feb 05, 2010	Jan	NEWA
AB		EQ 10MG BASE;20MG	A078466 004	Feb 05, 2010	Jan	NEWA
AB	MYLAN	EQ 2.5MG BASE;10MG	A077375 001	May 21, 2010	May	NEWA
AB		EQ 5MG BASE;10MG	A077375 002	May 21, 2010	May	NEWA
AB		EQ 5MG BASE;20MG	A077375 003	May 21, 2010	May	NEWA
AB		EQ 10MG BASE;20MG	A077375 004	May 21, 2010	May	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

TRIMOX

@ APOTHECON

50MG/ML

A061886 001

Feb DISC

@

125MG/5ML

A061886 002

Feb DISC

@

125MG/5ML

A062885 001

Feb DISC

@

250MG/5ML

A062885 002

Feb DISC

@

250MG/5ML

A061886 003

Feb DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'

AB GLAXOSMITHKLINE 125MG/5ML;EQ 31.25MG BASE/5ML N050575 001 Aug 06, 1984 Feb CMFD

AUGMENTIN '250'

>D> AB GLAXOSMITHKLINE 250MG/5ML;EQ 62.5MG BASE/5ML N050575 002 Aug 06, 1984 Jun CRLD

>A> AB + 250MG/5ML;EQ 62.5MG BASE/5ML N050575 002 Aug 06, 1984 Jun CRLD

AB 250MG/5ML;EQ 62.5MG BASE/5ML N050575 002 Aug 06, 1984 Feb CMFD

TABLET; ORAL

AUGMENTIN '250'

AB GLAXOSMITHKLINE 250MG;EQ 125MG BASE N050564 001 Aug 06, 1984 Feb CMFD

AUGMENTIN '500'

AB GLAXOSMITHKLINE 500MG;EQ 125MG BASE N050564 002 Aug 06, 1984 Feb CMFD

AUGMENTIN '875'

AB GLAXOSMITHKLINE 875MG;EQ 125MG BASE N050720 001 Feb 13, 1996 Feb CMFD

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB SANDOZ 1GM;EQ 62.5MG BASE A090227 001 Apr 21, 2010 Apr NEWA

AUGMENTIN XR

AB GLAXOSMITHKLINE 1GM;EQ 62.5MG BASE N050785 001 Sep 25, 2002 Feb CMFD

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ SIGMA TAU 5MG/ML N050724 001 Nov 20, 1995 Feb CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D> @ HANFORD GC EQ 250MG BASE/VIAL A063145 001 Apr 15, 1993 Jun CMFD

>A> AP EQ 250MG BASE/VIAL A063145 001 Apr 15, 1993 Jun CMFD

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP BIONICHE PHARMA EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL A065316 001 Jun 29, 2007 Mar CAHN

AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A065316 002 Jun 29, 2007 Mar CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>A> AB ACCORD HLTHCARE INC 1MG A090568 001 Jun 28, 2010 Jun NEWA

>A> AB DR REDDYS LABS LTD 1MG A090732 001 Jun 28, 2010 Jun NEWA

>A> AB FRESENIUS KABI ONCOL 1MG A090088 001 Jun 28, 2010 Jun NEWA

>A> AB MYLAN 1MG A091051 001 Jun 28, 2010 Jun NEWA

>A> AB NATCO PHARMA LTD 1MG A079220 001 Jun 28, 2010 Jun NEWA

>A> AB ROXANE 1MG A078485 001 Jun 28, 2010 Jun NEWA

>A> AB SANDOZ 1MG A079007 001 Jun 28, 2010 Jun NEWA

>A> AB STASON PHARMS 1MG A078944 001 Jun 28, 2010 Jun NEWA

>A> AB SYNTHON PHARMS 1MG A078322 001 Jun 28, 2010 Jun NEWA

>A> AB TEVA PHARMS 1MG A078058 001 Jun 28, 2010 Jun NEWA

>A> AB THREE RIVERS PHARMS 1MG A091164 001 Jun 28, 2010 Jun NEWA

>A> AB WATSON LABS 1MG A078984 001 Jun 28, 2010 Jun NEWA

>A> AB ZYDUS PHARMS USA INC 1MG A078921 001 Jun 28, 2010 Jun NEWA

TABLET; ORAL

ARIMIDEX

>D>	+	ASTRAZENECA	1MG	N020541 001	Dec 27, 1995	Jun	CFTG
>A>	AB	+	1MG	N020541 001	Dec 27, 1995	Jun	CFTG

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

@	IPSEN BIOPHARM LTD	20MG/2ML (10MG/ML)	N021264 001	Apr 20, 2004	May	CAHN
+		30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004	May	CAHN

ARMODAFINIL

TABLET; ORAL

NUVIGIL

@	CEPHALON	100MG	N021875 002	Mar 26, 2009	Feb	DISC
@		200MG	N021875 005	Mar 26, 2009	Feb	DISC

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+	NOVARTIS	20MG;120MG	N022268 001	Apr 07, 2009	Mar	CRLD
---	----------	------------	-------------	--------------	-----	------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

>A>		HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138 001	Jun 18, 2010	Jun	NEWA
-----	--	---------	---	-------------	--------------	-----	------

>A>	AP	ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE					
-----	----	--	--	--	--	--	--

PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466 001	Feb 26, 2010	Feb	NEWA
---------	---	-------------	--------------	-----	------

+	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466 002	Feb 26, 2010	Feb	NEWA
---	--	-------------	--------------	-----	------

SEPTOCAIN

>D>	+	DEPROCO	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971 001	Apr 03, 2000	Jun	CFTG
-----	---	---------	---	-------------	--------------	-----	------

>A>	AP	+	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971 001	Apr 03, 2000	Jun	CFTG
-----	----	---	---	-------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+	WATSON PHARMS	325MG;50MG;40MG	N017534 005	Apr 16, 1986	Feb	CTEC
----	---	---------------	-----------------	-------------	--------------	-----	------

LANORINAL

AA	LANNETT	325MG;50MG;40MG	A086996 002	Oct 11, 1985	Feb	CTEC
----	---------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710 002	Aug 23, 1983	Feb	CTEC
----	-------------------	-----------------	-------------	--------------	-----	------

AA	+	WEST WARD	325MG;50MG;40MG	A086162 002	Feb 16, 1984	Feb	CTEC
----	---	-----------	-----------------	-------------	--------------	-----	------

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

@	IVAX SUB TEVA PHARMS	325MG;400MG	A087211 001	Dec 22, 1982	Apr	DISC
---	----------------------	-------------	-------------	--------------	-----	------

+	STEVENS J	325MG;400MG	A081145 001	Jan 31, 1995	Apr	CRLD
---	-----------	-------------	-------------	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

WATSON LABS	325MG;4.5MG;0.38MG	A040255 001 Feb 27, 1998 May CRLD
PERCODAN		
@ ENDO PHARMS	325MG;4.5MG;0.38MG	N007337 006 May DISC

ATOVAQUONE

SUSPENSION; ORAL

MEPRON

>D>	+ GLAXOSMITHKLINE	750MG/5ML	N020500 001 Feb 08, 1995 Jun CAHN
>A>	+ GLAXOSMITHKLINE LLC	750MG/5ML	N020500 001 Feb 08, 1995 Jun CAHN

TABLET; ORAL

MEPRON

>D>	@ GLAXOSMITHKLINE	250MG	N020259 001 Nov 25, 1992 Jun CAHN
>A>	@ GLAXOSMITHKLINE LLC	250MG	N020259 001 Nov 25, 1992 Jun CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE PEDIATRIC

GLAXOSMITHKLINE	62.5MG;25MG	N021078 002 Jul 14, 2000 Apr CRLD
-----------------	-------------	-----------------------------------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

>A>	@ SUN PHARMA GLOBAL	0.05%	A078738 001 Jun 21, 2010 Jun DISC
-----	---------------------	-------	-----------------------------------

SPRAY, METERED; NASAL

ASTELIN

AB	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114 001 Nov 01, 1996 Jan CTEC
		AZELASTINE HYDROCHLORIDE	
AB	APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954 001 Apr 30, 2009 Jan CMFD

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP	GENERAMEDIX	EQ 500MG BASE/VIAL	A065501 001 Nov 09, 2009 Mar CAHN
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A065501 001 Nov 09, 2009 May CAHN
AP		EQ 500MG BASE/VIAL	A065501 001 Nov 09, 2009 Feb CAHN

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+ GILEAD	75MG/VIAL	N050814 001 Feb 22, 2010 Feb NEWA
----------	-----------	-----------------------------------

INJECTABLE; INJECTION

AZACTAM

>D>	+ BRISTOL MYERS SQUIBB	1GM/VIAL	N050580 002 Dec 31, 1986 Jun CFTG	
>A>	AP +	1GM/VIAL	N050580 002 Dec 31, 1986 Jun CFTG	
>D>	+	2GM/VIAL	N050580 003 Dec 31, 1986 Jun CFTG	
>A>	AP +	2GM/VIAL	N050580 003 Dec 31, 1986 Jun CFTG	
>A>		AZTREONAM		
>A>		APP PHARMS	500MG/VIAL	A065439 001 Jun 18, 2010 Jun NEWA
>A>	AP	1GM/VIAL	A065439 002 Jun 18, 2010 Jun NEWA	
>A>	AP	2GM/VIAL	A065439 003 Jun 18, 2010 Jun NEWA	

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

AP SAGENT PHARMS 50,000 UNITS/VIAL A090211 001 May 11, 2010 May NEWA

BACLOFEN

TABLET; ORAL

BACLOFEN

AB MATRIX LABS LTD 10MG A090334 001 Feb 18, 2010 Jan NEWA

AB 20MG A090334 002 Feb 18, 2010 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@ SCHWARZ PHARMA 10MG N021589 001 Oct 30, 2003 Jan DISC

@ 20MG N021589 002 Oct 30, 2003 Jan DISC

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+ TEVA BRANDED PHARM 0.04MG/INH N020911 002 Sep 15, 2000 Feb CAHN

QVAR 80

+ TEVA BRANDED PHARM 0.08MG/INH N020911 001 Sep 15, 2000 Feb CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB HUAHAI US INC 5MG A076118 001 Feb 11, 2004 Mar CAHN

AB 10MG A076118 002 Feb 11, 2004 Mar CAHN

AB 20MG A076118 003 Feb 11, 2004 Mar CAHN

AB 40MG A076118 004 Feb 11, 2004 Mar CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP PHARMAFORCE 1MG/ML A091152 001 Mar 29, 2010 Mar NEWA

TABLET; ORAL

BENZTROPINE MESYLATE

AA INVAGEN PHARMS 0.5MG A090294 001 Mar 29, 2010 Mar NEWA

AA 1MG A090294 002 Mar 29, 2010 Mar NEWA

AA 2MG A090294 003 Mar 29, 2010 Mar NEWA

AA + LANNETT 0.5MG A088877 001 Apr 11, 1985 Feb CAHN

AA + 1MG A088894 001 Apr 11, 1985 Feb CAHN

AA + 2MG A088895 001 Apr 11, 1985 Feb CAHN

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB LUITPOLD 3MG/ML; EQ 3MG BASE/ML A090747 001 Jul 31, 2009 Mar CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT AKORN EQ 0.5% BASE A075386 001 Jun 30, 2000 Jan CTNA

AT NOVEX EQ 0.5% BASE A075446 001 Sep 28, 2000 Jan CTNA

AT WOCKHARDT EQ 0.5% BASE A078694 001 Nov 16, 2009 Jan CAIN

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

AB	EPIC PHARMA	10MG	A075541 001	Oct 22, 1999	May	CAHN
AB	+	20MG	A075541 002	Oct 22, 1999	May	CAHN
AB	MIKAH PHARMA	10MG	A075541 001	Oct 22, 1999	Feb	CAHN
AB	+	20MG	A075541 002	Oct 22, 1999	Feb	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	EMCURE USA	5MG	A091256 001	May 04, 2010	Apr	NEWA
AA		10MG	A091256 002	May 04, 2010	Apr	NEWA
AA		25MG	A091256 003	May 04, 2010	Apr	NEWA
AA		50MG	A091256 004	May 04, 2010	Apr	NEWA

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	FRESENIUS KABI ONCOL	50MG	A079045 001	May 13, 2010	May	NEWA
----	----------------------	------	-------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	HOSPIRA	0.5%;0.005MG/ML	A071170 001	Jun 16, 1988	Mar	CMFD
AP	+	0.5%;0.005MG/ML	A071168 001	Jun 16, 1988	Mar	CTEC

>A> BUPRENORPHINE

>A>	FILM, EXTENDED RELEASE; TRANSDERMAL					
>A>	BUTTRANS					
>A>	PURDUE PHARMA LP	5MCG/HR	N021306 001	Jun 30, 2010	Jun	NEWA
>A>		10MCG/HR	N021306 002	Jun 30, 2010	Jun	NEWA
>A>	+	20MCG/HR	N021306 003	Jun 30, 2010	Jun	NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	BARR	EQ 2MG BASE	A090360 001	May 07, 2010	Apr	NEWA
AB		EQ 8MG BASE	A090360 002	May 07, 2010	Apr	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	MYLAN	100MG	A090325 001	Apr 08, 2010	Mar	NEWA
AB2		150MG	A090941 001	May 03, 2010	Apr	NEWA
AB1		150MG	A090325 002	Apr 08, 2010	Mar	NEWA
AB1		200MG	A090325 003	Apr 08, 2010	Mar	NEWA
AB1	SUN PHARMA GLOBAL	100MG	A078866 001	Apr 06, 2010	Mar	NEWA
AB1		150MG	A078866 002	Apr 06, 2010	Mar	NEWA
AB1		200MG	A078866 003	Apr 06, 2010	Mar	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

@ BRISTOL MYERS SQUIBB	10MG	N018731 002	Sep 29, 1986	Mar	DISC
@	15MG	N018731 003	Apr 22, 1996	Feb	DISC

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	+	IVAX SUB TEVA PHARMS	15MG	A075385 003	Mar 01, 2002	Mar	CRLD
AB		TEVA	30MG	A075022 004	Mar 25, 2004	Mar	CRLD
AB	+		30MG	A075022 004	Mar 25, 2004	Feb	CRLD

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

>A>	+	MYLAN	1%	N020524 001	Oct 18, 1996	Jun	CAHN
>D>	+	MYLAN BERTEK	1%	N020524 001	Oct 18, 1996	Jun	CAHN
		MENTAX-TC					
>A>	+	MYLAN	1%	N021408 001	Oct 17, 2002	Jun	CAHN
>D>	+	MYLAN BERTEK	1%	N021408 001	Oct 17, 2002	Jun	CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

>D>	AP	APOTEX INC	2MG/ML	A075697 001	Oct 23, 2001	Jun	CAHN
>A>	AP	CLARIS LIFESCIENCES	2MG/ML	A075697 001	Oct 23, 2001	Jun	CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE					
>D>	AP	APOTEX INC	1MG/ML	A075695 001	Oct 23, 2001	Jun	CAHN
>D>	AP		2MG/ML	A075695 002	Oct 23, 2001	Jun	CAHN
>A>	AP	CLARIS LIFESCIENCES	1MG/ML	A075695 001	Oct 23, 2001	Jun	CAHN
>A>	AP		2MG/ML	A075695 002	Oct 23, 2001	Jun	CAHN

CABAZITAXEL

SOLUTION; IV (INFUSION)

JEVTANA KIT

>A>	+	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023 001	Jun 17, 2010	Jun	NEWA
-----	---	-------------------	----------------------	-------------	--------------	-----	------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

>D>	AB	COBALT LABS INC	0.5MG	A078035 001	Apr 21, 2008	Jun	CAHN
	AB	IMPAX LABS INC	0.5MG	A077843 001	Jul 03, 2007	Mar	CAHN
>A>	AB	WATSON LABS	0.5MG	A078035 001	Apr 21, 2008	Jun	CAHN

CAFFEINE CITRATE

SOLUTION; ORAL

CAFFEINE CITRATE

AA		PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304 001	Sep 21, 2006	Apr	CAHN
----	--	--------------	---------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

OINTMENT; TOPICAL

CALCIPOTRIENE

+>	GLENMARK GENERICS	0.005%	A090633 001	Mar 24, 2010	Mar	NEWA
----	-------------------	--------	-------------	--------------	-----	------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;
SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

AT		B BRAUN	0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9M G/ML; 6.4MG/ML; 1.7MG/ML	A091387 001	Feb 03, 2010	Jan	NEWA
----	--	---------	--	-------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL
Captopril

AB	HUAHAI US INC	12.5MG	A074477 001	Feb 13, 1996	Apr	CAHN
AB		25MG	A074477 002	Feb 13, 1996	Apr	CAHN
AB		50MG	A074477 003	Feb 13, 1996	Apr	CAHN
AB		100MG	A074477 004	Feb 13, 1996	Apr	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
Captopril And Hydrochlorothiazide

@	IVAX SUB TEVA PHARMS	25MG;15MG	A075055 001	Jun 18, 1998	Apr	DISC
@		25MG;25MG	A075055 002	Jun 18, 1998	Apr	DISC
@		50MG;15MG	A075055 004	Jun 18, 1998	Apr	DISC
@		50MG;25MG	A075055 003	Jun 18, 1998	Apr	DISC

CARBAMAZEPINE

TABLET; ORAL
Carbamazepine

@	INWOOD LABS	200MG	A070231 001	Aug 14, 1986	Apr	DISC
---	-------------	-------	-------------	--------------	-----	------

CARBIDOPA

TABLET; ORAL
Lodosyn

+	ATON	25MG	N017830 001		Apr	CAHN
---	------	------	-------------	--	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL
Carbidopa And Levodopa

AB	IMPAX LABS	10MG;100MG	A090631 001	Jun 08, 2010	May	NEWA
AB		25MG;100MG	A090631 002	Jun 08, 2010	May	NEWA
AB		25MG;250MG	A090631 003	Jun 08, 2010	May	NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL
Carbinoxamine Maleate

AA	CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010	Apr	NEWA
TABLET; ORAL						
AA	INVAGEN PHARMS	4MG	A090435 001	Apr 15, 2010	Mar	NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)
Carboplatin

AP	BIONICHE PHARMA USA	50MG/5ML (10MG/ML)	A077998 001	Apr 24, 2007	Mar	CAHN	
AP		150MG/15ML (10MG/ML)	A077998 002	Apr 24, 2007	Mar	CAHN	
AP		450MG/45ML (10MG/ML)	A077998 003	Apr 24, 2007	Mar	CAHN	
>D>	AP	SUN PHARM IND	50MG/5ML (10MG/ML)	A077926 001	Sep 19, 2008	Jun	CAHN
>D>	AP		150MG/15ML (10MG/ML)	A077926 002	Sep 19, 2008	Jun	CAHN
>D>	AP		450MG/45ML (10MG/ML)	A077926 003	Sep 19, 2008	Jun	CAHN
>A>	AP	SUN PHARMA GLOBAL	50MG/5ML (10MG/ML)	A077926 001	Sep 19, 2008	Jun	CAHN
>A>	AP		150MG/15ML (10MG/ML)	A077926 002	Sep 19, 2008	Jun	CAHN
>A>	AP		450MG/45ML (10MG/ML)	A077926 003	Sep 19, 2008	Jun	CAHN

CARGLUMIC ACID

TABLET; ORAL
 CARBAGLU
 + ORPHAN EUROPE 200MG N022562 001 Mar 18, 2010 Mar NEWA

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
 COREG CR
 + SB PHARMCO 40MG N022012 003 Oct 20, 2006 Feb CRLD
 80MG N022012 004 Oct 20, 2006 Feb CRLD

CEFACLOR

CAPSULE; ORAL
 CEFACLOR
 >D> AB HIKMA EQ 500MG BASE A065350 002 Apr 03, 2007 Jun CRLD
 >A> AB + EQ 500MG BASE A065350 002 Apr 03, 2007 Jun CRLD
 >D> AB + RANBAXY EQ 500MG BASE A064156 002 Aug 28, 1997 Jun CRLD
 >A> AB EQ 500MG BASE A064156 002 Aug 28, 1997 Jun CRLD
 FOR SUSPENSION; ORAL
 CEFACLOR
 >A> @ ACS DOBFAR INFO SA EQ 125MG BASE/5ML A062206 001 Jun CAHN
 >A> @ EQ 187MG BASE/5ML A062206 003 Apr 20, 1988 Jun CAHN
 >A> @ EQ 250MG BASE/5ML A062206 002 Jun CAHN
 >A> @ EQ 375MG BASE/5ML A062206 004 Apr 20, 1988 Jun CAHN
 >D> @ CEPH INTL EQ 125MG BASE/5ML A062206 001 Jun CAHN
 >D> @ EQ 187MG BASE/5ML A062206 003 Apr 20, 1988 Jun CAHN
 >D> @ EQ 250MG BASE/5ML A062206 002 Jun CAHN
 >D> @ EQ 375MG BASE/5ML A062206 004 Apr 20, 1988 Jun CAHN
 TABLET, EXTENDED RELEASE; ORAL
 CEFACLOR
 AB + WORLD GEN EQ 500MG BASE A065057 001 Jan 05, 2001 Mar CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
 CEFADROXIL
 AB + TEVA PHARMS EQ 500MG BASE A065282 001 Jan 20, 2006 Mar CRLD
 FOR SUSPENSION; ORAL
 CEFADROXIL
 AB + LUPIN EQ 500MG BASE/5ML A065396 002 Feb 21, 2008 Jan CRLD
 DURICEF
 @ WARNER CHILCOTT EQ 250MG BASE/5ML N050527 003 Jan DISC
 @ EQ 500MG BASE/5ML N050527 001 Jan DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
 CEFAZOLIN SODIUM
 @ STERI PHARMA EQ 500MG BASE/VIAL A063214 001 Dec 27, 1991 May CAHN
 @ EQ 500MG BASE/VIAL A063216 001 Dec 27, 1991 May CAHN
 AP EQ 1GM BASE/VIAL A063208 001 Dec 27, 1991 May CAHN
 AP EQ 1GM BASE/VIAL A063207 001 Dec 27, 1991 May CAHN
 AP EQ 10GM BASE/VIAL A063209 001 Dec 27, 1991 May CAHN
 >A> AP EQ 20GM BASE/VIAL A063209 002 Apr 30, 1999 Jun NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN	EQ 1GM BASE/VIAL	N050821 001 May 06, 2010 May NEWA
	EQ 2GM BASE/VIAL	N050821 002 May 06, 2010 May NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348 001 Jan 25, 2010 Jan NEWA
---------------------	-------------------	-----------------------------------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP ACS DOB FAR	EQ 10GM BASE/VIAL	A065415 001 May 19, 2010 May NEWA
AP HIKMA FARMACEUTICA	EQ 1GM BASE/VIAL	A065238 001 Mar 12, 2010 Feb NEWA
AP	EQ 2GM BASE/VIAL	A065238 002 Mar 12, 2010 Feb NEWA
AP	EQ 10GM BASE/VIAL	A065239 001 Mar 02, 2010 Feb NEWA

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB + LUPIN	250MG/5ML	A065261 002 Dec 19, 2005 Feb CTEC
TABLET; ORAL		
CEFPROZIL		
AB + LUPIN	500MG	A065276 002 Dec 08, 2005 Feb CRLD

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP AUROBINDO PHARMA	500MG/VIAL	A065481 001 May 28, 2010 May NEWA
AP	1GM/VIAL	A065481 002 May 28, 2010 May NEWA
AP	2GM/VIAL	A065481 003 May 28, 2010 May NEWA
AP	6GM/VIAL	A065482 001 May 28, 2010 May NEWA

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ PERNIX THERAP	EQ 400MG BASE	N050685 002 Dec 20, 1995 May CAHN
FOR SUSPENSION; ORAL		
CEDAX		
+ PERNIX THERAP	EQ 90MG BASE/5ML	N050686 001 Dec 20, 1995 May CAHN
@	EQ 180MG BASE/5ML	N050686 002 Dec 20, 1995 May CAHN

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP STERI PHARMA	EQ 1GM BASE/VIAL	A065268 001 Feb 28, 2007 May CAHN
AP	EQ 2GM BASE/VIAL	A065268 002 Feb 28, 2007 May CAHN

INJECTABLE; INJECTION

CEFTRIAXONE

AP STERI PHARMA	EQ 10GM BASE/VIAL	A065269 001 Feb 28, 2007 May CAHN
-----------------	-------------------	-----------------------------------

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	NEWA
AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	NEWA

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	STERI PHARMA	EQ 750MG BASE/VIAL	A064125 001	May 30, 1997	May	CAHN
----	--------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	STERI PHARMA	EQ 1.5GM BASE/VIAL	A064125 002	May 30, 1997	May	CAHN
AP		EQ 7.5GM BASE/VIAL	A064124 001	May 30, 1997	May	CAHN

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

>A>	AB	ACS DOBFAR INFO SA	EQ 500MG BASE	A062118 002	Jun	CAHN
>D>	AB	CEPH INTL	EQ 500MG BASE	A062118 002	Jun	CAHN
		@ IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001	Apr	DISC
		@	EQ 500MG BASE	A061969 002	Apr	DISC

FOR SUSPENSION; ORAL

CEPHALEXIN

>A>		@ ACS DOBFAR INFO SA	EQ 100MG BASE/ML	A062117 001	Jun	CAHN
>A>	AB		EQ 125MG BASE/5ML	A062117 002	Jun	CAHN
>A>	AB	+	EQ 250MG BASE/5ML	A062117 003	Jun	CAHN
>D>		@ CEPH INTL	EQ 100MG BASE/ML	A062117 001	Jun	CAHN
>D>	AB		EQ 125MG BASE/5ML	A062117 002	Jun	CAHN
>D>	AB	+	EQ 250MG BASE/5ML	A062117 003	Jun	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010	Jan	NEWA
----	----------------------	---------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	IPCA LABS LTD	EQ 150MG BASE	A090610 001	Dec 03, 2009	May	CAHN
AA		EQ 300MG BASE	A090249 001	Dec 03, 2009	Apr	CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	MIKART	375MG	A040861 001	Jun 01, 2010	May	NEWA
		750MG	A040861 002	Jun 01, 2010	May	NEWA

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	NYCOMED US	1%	A090146 001	May 25, 2010	May	NEWA
AT	PERRIGO	1%	A078594 001	Feb 16, 2010	Jan	NEWA

SOLUTION; TOPICAL

CICLOPIROX

AT VERSAPHARM 8%

A078975 001 Feb 17, 2010 Jan NEWA

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ IVAX SUB TEVA PHARMS 100MG

A077020 002 Mar 01, 2005 Apr DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPRO

AB + BAYER HLTHCARE EQ 500MG BASE

N019537 003 Oct 22, 1987 Feb CRLD

AB EQ 750MG BASE

N019537 004 Oct 22, 1987 Feb CRLD

CIPROFLOXACIN HYDROCHLORIDE

>D> AB COBALT EQ 100MG BASE

A076794 001 Feb 10, 2005 Jun CAHN

>D> AB EQ 250MG BASE

A076794 002 Jun 09, 2004 Jun CAHN

>D> AB EQ 500MG BASE

A076794 003 Jun 09, 2004 Jun CAHN

>D> AB EQ 750MG BASE

A076794 004 Jun 09, 2004 Jun CAHN

>A> AB WATSON LABS EQ 100MG BASE

A076794 001 Feb 10, 2005 Jun CAHN

>A> AB EQ 250MG BASE

A076794 002 Jun 09, 2004 Jun CAHN

>A> AB EQ 500MG BASE

A076794 003 Jun 09, 2004 Jun CAHN

>A> AB EQ 750MG BASE

A076794 004 Jun 09, 2004 Jun CAHN

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D> AB COBALT EQ 10MG BASE

A077034 001 Jun 30, 2005 Jun CAHN

>D> AB EQ 20MG BASE

A077034 002 Jun 30, 2005 Jun CAHN

>D> AB EQ 40MG BASE

A077034 003 Jun 30, 2005 Jun CAHN

AB EPIC PHARMA EQ 10MG BASE

A077045 003 Apr 29, 2005 May CMFD

AB EQ 20MG BASE

A077045 002 Apr 29, 2005 May CMFD

AB EQ 40MG BASE

A077045 001 Apr 29, 2005 May CMFD

>A> AB WATSON LABS EQ 10MG BASE

A077034 001 Jun 30, 2005 Jun CAHN

>A> AB EQ 20MG BASE

A077034 002 Jun 30, 2005 Jun CAHN

>A> AB EQ 40MG BASE

A077034 003 Jun 30, 2005 Jun CAHN

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@ IVAX SUB TEVA PHARMS 250MG

A065137 001 May 31, 2005 Apr DISC

@ 500MG

A065137 002 May 31, 2005 Apr DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

>D> + PHARMACIA AND UPJOHN EQ 75MG BASE/5ML

A062644 001 Apr 07, 1986 Jun CFTG

>A> AB + EQ 75MG BASE/5ML

A062644 001 Apr 07, 1986 Jun CFTG

>A> CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A> AB PADDOCK LABS EQ 75MG BASE/5ML

A090902 001 Jul 07, 2010 Jun NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

>D> AT COBREK PHARMS 1%

A090785 001 Mar 31, 2010 Jun CAHN

AT 1%

A090785 001 Mar 31, 2010 Mar NEWA

		AEROSOL, FOAM; TOPICAL CLINDAMYCIN PHOSPHATE					
>A>	AT	PERRIGO EVOCLIN	1%		A090785	001 Mar 31, 2010 Jun	CAHN
AT	+	STIEFEL LABS INC	1%		N050801	001 Oct 22, 2004 Mar	CFTG
		CREAM; VAGINAL CLINDAMYCIN PHOSPHATE					
AB		NYCOMED US	EQ 2% BASE		A065139	001 Dec 27, 2004 Mar	CAHN
		SOLUTION; TOPICAL CLINDAMYCIN PHOSPHATE					
AT		VERSAPHARM	EQ 1% BASE		A065513	001 Jun 17, 2010 May	NEWA
		<u>CLOBETASOL PROPIONATE</u>					
		OINTMENT; TOPICAL CLOBETASOL PROPIONATE					
AB		NYCOMED US	0.05%		A074407	001 Feb 23, 1996 Mar	CAHN
		<u>CLONIDINE HYDROCHLORIDE</u>					
		INJECTABLE; INJECTION DURACLON					
AP		BIONICHE PHARMA USA	1 MG/10 ML (0.1 MG/ML)		N020615	001 Oct 02, 1996 Mar	CAHN
AP	+		5 MG/10 ML (0.5 MG/ML)		N020615	002 Apr 27, 1999 Mar	CAHN
		TABLET; ORAL CLONIDINE HYDROCHLORIDE					
		@ INTERPHARM	0.1MG		A071252	001 Oct 01, 1986 May	CAHN
		@	0.2MG		A071253	001 Oct 01, 1986 May	CAHN
		@	0.3MG		A071254	001 Oct 01, 1986 May	CAHN
>A>		JENLOGA					
>A>	BX	SHIONOGI PHARMA	0.2MG		N022331	002 May 25, 2010 Jun	NEWA
		<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>					
		SYRUP; ORAL PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
AA		SUN PHARM INDUS INC	10MG/5ML;6.25MG/5ML		A090180	001 Mar 17, 2010 Mar	NEWA
		<u>COLCHICINE; PROBENECID</u>					
		TABLET; ORAL PROBENECID AND COLCHICINE					
		@ IVAX SUB TEVA PHARMS	0.5MG;500MG		A083734	001 Apr	DISC
		<u>COSYNTROPIN</u>					
		INJECTABLE; INJECTION COSYNTROPIN					
AP		BIONICHE PHARMA	0.25MG/VIAL		A090574	001 Dec 17, 2009 Mar	CAHN
		<u>CROMOLYN SODIUM</u>					
		CONCENTRATE; ORAL CROMOLYN SODIUM					
		@ GENERA PHARMS	100MG/5ML		A090954	001 Dec 18, 2009 Apr	DISC
		GASTROCROM					
	+	AZUR PHARMA	100MG/5ML		N020479	001 Feb 29, 1996 Apr	CTEC
		SOLUTION; INHALATION CROMOLYN SODIUM					
>D>	AN	RESPIRARE	10MG/ML		A076469	001 Jun 17, 2005 Jun	CAHN
>A>	AN	WATSON LABS	10MG/ML		A076469	001 Jun 17, 2005 Jun	CAHN

CYANOCOBALAMIN

SPRAY, METERED; NASAL
 CALOMIST
 @ FLEMING 25MCG/SPRAY N022102 001 Jul 27, 2007 Jan DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
 CYTOXAN

AP + BAXTER HLTHCARE	500MG/VIAL	N012142 003	Feb	CMFD	
AP +	1GM/VIAL	N012142 004	Aug 30, 1982	Feb	CMFD
AP +	2GM/VIAL	N012142 005	Aug 30, 1982	Feb	CMFD
LYOPHILIZED CYTOXAN					
@ BAXTER HLTHCARE	100MG/VIAL	N012142 006	Dec 05, 1985	Feb	DISC
@	200MG/VIAL	N012142 007	Dec 10, 1985	Feb	DISC
@	500MG/VIAL	N012142 008	Jan 04, 1984	Feb	DISC
@	1GM/VIAL	N012142 010	Sep 24, 1985	Feb	DISC
@	2GM/VIAL	N012142 009	Dec 10, 1984	Feb	DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
 CYPROHEPTADINE HYDROCHLORIDE
 @ PLIVA 4MG A088205 001 Jul 26, 1983 May DISC

CYTARABINE

INJECTABLE; INJECTION
 CYTARABINE

AP + HOSPIRA	20MG/ML	A071868 001	Jun 04, 1990	Apr	CRLD
AP +	20MG/ML	A072168 001	Aug 31, 1990	Mar	CRLD

DACTINOMYCIN

INJECTABLE; INJECTION
 COSMEGEN

AP + LUNDBECK INC	0.5MG/VIAL	N050682 001	Mar	CFTG	
DACTINOMYCIN					
AP BEDFORD	0.5MG/VIAL	A090304 001	Mar 16, 2010	Mar	NEWA

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL
 AMPYRA
 + ACORDA 10MG N022250 001 Jan 22, 2010 Jan NEWA

DARUNAVIR ETHANOLATE

TABLET; ORAL
 PREZISTA

TIBOTEC	EQ 75MG BASE	N021976 004	Dec 18, 2008	May	CAHN
	EQ 150MG BASE	N021976 005	Dec 18, 2008	May	CAHN
	EQ 300MG BASE	N021976 001	Jun 23, 2006	May	CAHN
	EQ 400MG BASE	N021976 003	Oct 21, 2008	May	CAHN
+	EQ 600MG BASE	N021976 002	Feb 25, 2008	May	CAHN

DESLORATADINE

TABLET; ORAL
 CLARINEX

AB + SCHERING PLOUGH	5MG	N021165 001	Dec 21, 2001	Jan	CFTG
----------------------	-----	-------------	--------------	-----	------

TABLET; ORAL

DESLORATADINE

AB	ORCHID HLTHCARE	5MG	A078357 001	Feb 19, 2010	Jan	NEWA
<u>TABLET, ORALLY DISINTEGRATING; ORAL</u>						
	CLARINEX					
>D>	SCHERING	2.5MG	N021312 002	Jul 14, 2005	Jun	CFTG
>A> AB		2.5MG	N021312 002	Jul 14, 2005	Jun	CFTG
>D>	+	5MG	N021312 001	Jun 26, 2002	Jun	CFTG
>A> AB	+	5MG	N021312 001	Jun 26, 2002	Jun	CFTG
>A>	DESLORATADINE					
>A> AB	REDDYS	2.5MG	A078367 001	Jul 12, 2010	Jun	NEWA
>A> AB		5MG	A078367 002	Jul 12, 2010	Jun	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE (NEEDS NO REFRIGERATION)

>D>	@ CSL BEHRING	1.5MG/SPRAY	N020355 002	Oct 24, 2007	Jun	CMFD
>A>	+	1.5MG/SPRAY	N020355 002	Oct 24, 2007	Jun	CMFD
	@	1.5MG/SPRAY	N020355 002	Oct 24, 2007	Jan	DISC

DESOGESTREL; ETHINYLL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB	+	TEVA WOMENS	0.15MG,N/A;0.02MG,0.01MG	N020713 001	Apr 22, 1998	Apr	CAHN
----	---	-------------	--------------------------	-------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>A> AB	NYCOMED US	0.25%	A078369 001	Jun 29, 2010	Jun	NEWA
--------	------------	-------	-------------	--------------	-----	------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

TAKEDA PHARMS

+ 60MG

N022287 001 Jan 30, 2009 Mar CTNA
N022287 002 Jan 30, 2009 Mar CTNADEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

+ HOSPIRA EQ 100MCG BASE/ML (EQ100MCG
BASE/ML)

N021038 001 Dec 17, 1999 Jan CAIN

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

@ GE HEALTHCARE 100%

N011386 001 May DISC

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

@ TEVA BRANDED PHARM 50MG

N017425 001 Feb CAHN

@ 100MG

N017425 002 Feb CAHN

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL
CAMBIA
+ NAUTILUS NEUROSCIENC 50MG N022165 001 Jun 17, 2009 Mar CAHN
TABLET; ORAL
DICLOFENAC POTASSIUM
@ SANDOZ 50MG A075582 001 Feb 23, 2001 Jan DISC
@ WATSON LABS 50MG A075152 001 Nov 27, 1998 Apr DISC

DICLOFENAC SODIUM

SOLUTION; TOPICAL
PENNSAID
+ MALLINCKRODT 1.5% N020947 001 Nov 04, 2009 May CAHN
TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM
@ NOSTRUM LABS 50MG A074986 001 Feb 26, 1999 Apr DISC
@ 75MG A074986 002 Feb 26, 1999 Apr DISC

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL
DIDANOSINE
AB MATRIX LABS LTD 125MG A090788 001 Apr 08, 2010 Mar NEWA
AB 200MG A090788 002 Apr 08, 2010 Mar NEWA
AB 250MG A090788 003 Apr 08, 2010 Mar NEWA
AB 400MG A090788 004 Apr 08, 2010 Mar NEWA

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL-28
NATAZIA
>D> BAYER HLTHCARE N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1 MG,N/A N022252 001 May 06, 2010 Jun CRLD
>A> + N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1 MG,N/A N022252 001 May 06, 2010 Jun CRLD
N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1 MG,N/A N022252 001 May 06, 2010 May NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE
AB1 + ALTANA 0.05% A075187 001 Mar 30, 1998 Mar CRLD
PSORCON
@ SANOFI AVENTIS US 0.05% N020205 001 Nov 20, 1992 Feb DISC

DIFLUPREDNATE

EMULSION; OPHTHALMIC
DUREZOL
>A> + ALCON RES 0.05% N022212 001 Jun 23, 2008 Jun CAHN
>D> + SIRION THERAP 0.05% N022212 001 Jun 23, 2008 Jun CAHN

DIGOXIN

CAPSULE; ORAL
LANOXICAPS
>A> GLAXOSMITHKLINE LLC 0.05MG N018118 002 Jul 26, 1982 Jun CAHN
>A> 0.1MG N018118 003 Jul 26, 1982 Jun CAHN
>A> @ 0.15MG N018118 004 Sep 24, 1984 Jun CAHN
>A> + 0.2MG N018118 001 Jul 26, 1982 Jun CAHN

CAPSULE; ORALLANOXICAPS

>D>	SMITHKLINE BEECHAM	0.05MG	N018118 002	Jul 26, 1982	Jun	CAHN
>D>		0.1MG	N018118 003	Jul 26, 1982	Jun	CAHN
>D>	@	0.15MG	N018118 004	Sep 24, 1984	Jun	CAHN
>D>	+	0.2MG	N018118 001	Jul 26, 1982	Jun	CAHN

INJECTABLE; INJECTIONLANOXIN

>D> AP	+	GLAXOSMITHKLINE	0.25MG/ML	N009330 002	Jun	CAHN
>A> AP	+	GLAXOSMITHKLINE LLC	0.25MG/ML	N009330 002	Jun	CAHN
		LANOXIN PEDIATRIC				
>D>	+	GLAXOSMITHKLINE	0.1MG/ML	N009330 004	Jun	CAHN
>A>	+	GLAXOSMITHKLINE LLC	0.1MG/ML	N009330 004	Jun	CAHN

TABLET; ORALLANOXIN

>A>	@	GLAXOSMITHKLINE LLC	0.5MG	N020405 006	Sep 30, 1997	Jun	CAHN
>D>	@	SMITHKLINE BEECHAM	0.5MG	N020405 006	Sep 30, 1997	Jun	CAHN

DILTIAZEM HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALCARDIZEM LA

AB	BIOVAIL LABS INTL	120MG	N021392 001	Feb 06, 2003	Feb	CFTG
AB		180MG	N021392 002	Feb 06, 2003	Feb	CFTG
AB		240MG	N021392 003	Feb 06, 2003	Feb	CFTG
AB		300MG	N021392 004	Feb 06, 2003	Feb	CFTG
AB		360MG	N021392 005	Feb 06, 2003	Feb	CFTG
AB	+	420MG	N021392 006	Feb 06, 2003	Feb	CFTG

DILTIAZEM HYDROCHLORIDE

AB	WATSON LABS FLORIDA	120MG	A077686 006	Mar 15, 2010	Feb	NEWA
AB		180MG	A077686 005	Mar 15, 2010	Feb	NEWA
AB		240MG	A077686 004	Mar 15, 2010	Feb	NEWA
AB		300MG	A077686 003	Mar 15, 2010	Feb	NEWA
AB		360MG	A077686 002	Mar 15, 2010	Feb	NEWA
AB		420MG	A077686 001	Mar 15, 2010	Feb	NEWA

DIPYRIDAMOLEINJECTABLE; INJECTIONDIPYRIDAMOLE

>D> AP	APOTEX INC	5MG/ML	A075769 001	Nov 27, 2002	Jun	CAHN
>A> AP	CLARIS LIFESCIENCES	5MG/ML	A075769 001	Nov 27, 2002	Jun	CAHN

DISOPYRAMIDE PHOSPHATECAPSULE; ORALDISOPYRAMIDE PHOSPHATE

@ INTERPHARM		EQ 100MG BASE	A071190 001	Jan 15, 1987	May	CAHN
@		EQ 150MG BASE	A071191 001	Jan 15, 1987	May	CAHN

DOXAZOSIN MESYLATETABLET; ORALDOXAZOSIN MESYLATE

@ IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453 001	Oct 18, 2000	Apr	DISC
@	EQ 2MG BASE	A075453 002	Oct 18, 2000	Apr	DISC
@	EQ 4MG BASE	A075453 003	Oct 18, 2000	Apr	DISC
@	EQ 8MG BASE	A075453 004	Oct 18, 2000	Apr	DISC

DOXE PIN HYDROCHLORIDE

TABLET; ORAL							
SILENOR							
SOMAXON	EQ 3MG BASE						
+	EQ 6MG BASE						
		N022036 001	Mar 17, 2010	Mar	NEWA		
		N022036 002	Mar 17, 2010	Mar	NEWA		

DOXYCYCLINE

CAPSULE; ORAL							
>A>	DOXYCYCLINE						
>A> AB	MYLAN	40MG					
	ORACEA						
>D>	+	GALDERMA LABS LP	40MG				
>A> AB	+		40MG				
				N050805 001	May 26, 2006	Jun	CFTG
				N050805 001	May 26, 2006	Jun	CFTG

DOXYCYCLINE HYCLATE

CAPSULE; ORAL							
DOXYCYCLINE HYCLATE							
@ INTERPHARM	EQ 50MG BASE						
@	EQ 100MG BASE						
CAPSULE, DELAYED RELEASE; ORAL							
DOXYCYCLINE HYCLATE							
>A> MEDICIS	EQ 75MG BASE						
>A> +	EQ 100MG BASE						
>D> SANDOZ	EQ 75MG BASE						
>D> +	EQ 100MG BASE						
TABLET; ORAL							
DOXYCYCLINE HYCLATE							
@ INTERPHARM	EQ 100MG BASE						
@ LARKEN LABS	EQ 20MG BASE						
		A062763 001	Sep 02, 1988	May	CAHN		
		A062763 002	Sep 02, 1988	May	CAHN		
		A065281 001	Dec 21, 2005	Jun	CAHN		
		A065281 002	Dec 21, 2005	Jun	CAHN		
		A065281 001	Dec 21, 2005	Jun	CAHN		
		A065281 002	Dec 21, 2005	Jun	CAHN		
		A062764 001	Sep 02, 1988	May	CAHN		
		A065287 001	Feb 28, 2006	Apr	CAHN		

DRONABINOL

CAPSULE; ORAL							
MARINOL							
AB ABBOTT PRODS	2.5MG						
AB +	5MG						
AB	10MG						
		N018651 001	May 31, 1985	May	CAHN		
		N018651 002	May 31, 1985	May	CAHN		
		N018651 003	May 31, 1985	May	CAHN		

>A> DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL							
JALYN							
>A> + GLAXOSMITHKLINE	0.5MG;0.4MG						
		N022460 001	Jun 14, 2010	Jun	NEWA		

ELTROMBOPAG OLAMINE

TABLET; ORAL							
PROMACTA							
GLAXOSMITHKLINE	EQ 75MG ACID						
		N022291 003	Sep 08, 2009	Mar	NEWA		

ENALAPRIL MALEATE

TABLET; ORAL							
ENALAPRIL MALEATE							
AB MYLAN	2.5MG						
AB	5MG						
AB	10MG						
AB	20MG						
		A075472 001	Aug 22, 2000	Apr	CAHN		
		A075472 002	Aug 22, 2000	Apr	CAHN		
		A075472 003	Aug 22, 2000	Apr	CAHN		
		A075472 004	Aug 22, 2000	Apr	CAHN		

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL
@ ASTRAZENECA

5MG;5MG

N020668 001 Dec 27, 1996 Mar DISC

EPINEPHRINE

INJECTABLE; IM-SC
ADRENACLICK

BX	+	SHIONOGI PHARMA	EQ 0.15MG /DELIVERY	N020800 003 Nov 25, 2009 Apr CTEC
	+		EQ 0.15MG /DELIVERY	N020800 003 Nov 25, 2009 Mar NEWA
BX	+		EQ 0.3MG /DELIVERY	N020800 004 Nov 25, 2009 Apr CTEC
	+		EQ 0.3MG /DELIVERY	N020800 004 Nov 25, 2009 Mar NEWA
		EPIPEN		
BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430 001 Dec 22, 1987 Apr CDFR
		EPIPEN JR.		
BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430 002 Dec 22, 1987 Apr CDFR
		TWINJECT 0.15		
BX	+	SHIONOGI PHARMA	EQ 0.15MG /DELIVERY	N020800 002 May 28, 2004 Apr CTEC
	+		EQ 0.15MG /DELIVERY	N020800 002 May 28, 2004 Jan CAHN
		TWINJECT 0.3		
BX	+	SHIONOGI PHARMA	EQ 0.3MG /DELIVERY	N020800 001 May 30, 2003 Apr CTEC
	+		EQ 0.3MG /DELIVERY	N020800 001 May 30, 2003 Jan CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

AP		BIONICHE PHARMA USA	50MG/25ML (2MG/ML)	A065371 001 Nov 28, 2007 Mar CAHN
AP			200MG/100ML (2MG/ML)	A065371 002 Nov 28, 2007 Mar CAHN
AP	X	GEN PHARMS	50MG/25ML (2MG/ML)	A090075 001 Mar 25, 2010 Mar NEWA
AP			200MG/100ML (2MG/ML)	A090075 002 Mar 25, 2010 Mar NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
FLOLAN

>D>	AP	+	GLAXOSMITHKLINE	EQ 0.5MG BASE/VIAL	N020444 001 Sep 20, 1995 Jun CAHN
>D>	AP	+		EQ 1.5MG BASE/VIAL	N020444 002 Sep 20, 1995 Jun CAHN
>A>	AP	+	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444 001 Sep 20, 1995 Jun CAHN
>A>	AP	+		EQ 1.5MG BASE/VIAL	N020444 002 Sep 20, 1995 Jun CAHN

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AT		AKORN	0.5%	A064030 001 Jul 18, 1996 Apr CMFD
----	--	-------	------	-----------------------------------

SWAB; TOPICAL
ERYTHROMYCIN

AT		VERSAPHARM	2%	A090215 001 May 12, 2010 May NEWA
----	--	------------	----	-----------------------------------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

>D>		+	BAXTER HLTHCARE CORP	20MG/ML	N019386 007 May 28, 2003 Jun DISC
>A>		@		20MG/ML	N019386 007 May 28, 2003 Jun DISC

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL
VIMOVO

>A>	ASTRAZENECA LP	EQ 20MG BASE;375MG	N022511 002	Apr 30, 2010	Jun	CAHN
>A>	+	EQ 20MG BASE;500MG	N022511 001	Apr 30, 2010	Jun	CAHN
>D>	POZEN	EQ 20MG BASE;375MG	N022511 002	Apr 30, 2010	Jun	CAHN
		EQ 20MG BASE;375MG	N022511 002	Apr 30, 2010	Apr	NEWA
>D>	+	EQ 20MG BASE;500MG	N022511 001	Apr 30, 2010	Jun	CAHN
	+	EQ 20MG BASE;500MG	N022511 001	Apr 30, 2010	Apr	NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

AO	PHARMAFORCE	20MG/ML	A090920 001	Jan 19, 2010	Jan	NEWA
AO		40MG/ML	A090920 002	Jan 19, 2010	Jan	NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

AB	BARR	1MG;0.5MG	A079193 001	May 11, 2010	May	NEWA
----	------	-----------	-------------	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL
CENESTIN

TEVA WOMENS	0.3MG	N020992 001	Jun 21, 2002	Apr	CAHN
	0.45MG	N020992 005	Feb 05, 2004	Apr	CAHN
	0.625MG	N020992 002	Mar 24, 1999	Apr	CAHN
	0.9MG	N020992 003	Mar 24, 1999	Apr	CAHN
+	1.25MG	N020992 004	Mar 13, 2000	Apr	CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL
ENJUVIA

TEVA WOMENS	0.3MG	N021443 001	Dec 20, 2004	Apr	CAHN
	0.45MG	N021443 002	Dec 20, 2004	Apr	CAHN
	0.625MG	N021443 003	May 10, 2004	Apr	CAHN
	0.9MG	N021443 005	Apr 27, 2007	Apr	CAHN
+	1.25MG	N021443 004	May 10, 2004	Apr	CAHN

ETHINYLMESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYLMESTRADIOL

WATSON LABS	0.035MG;0.4MG	A078379 001	Feb 23, 2010	Feb	NEWA
-------------	---------------	-------------	--------------	-----	------

TABLET; ORAL-28

NORETHINDRONE AND ETHINYLMESTRADIOL

AB	WATSON LABS	0.035MG;0.4MG	A078323 001	Feb 04, 2010	Jan	NEWA
AB		0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A076393 001	Feb 04, 2010	Jan	NEWA

ETHINYLMESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
NORETHINDRONE ACETATE AND ETHINYLMESTRADIOL AND FERROUS FUMARATE

AB	WATSON LABS	0.02MG;1MG	A078267 001	Sep 01, 2009	Jan	CDFR
----	-------------	------------	-------------	--------------	-----	------

TABLET; ORAL-28

	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	WATSON LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Mar	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Feb	CAHN
AB		0.03MG;1.5MG	A077075	001	Apr 28, 2005	Feb	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

	PREVIFEM						
AB	VINTAGE	0.035MG;0.25MG	A076334	001	Jan 09, 2004	Feb	CAHN
	TRI-PREVIFEM						
AB	VINTAGE	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335	001	Mar 26, 2004	Feb	CAHN

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

	ETHIODOL						
	GUERBET	99%	N009190	001		May	CAHN

EVEROLIMUS

TABLET; ORAL

	AFINITOR						
>A>	NOVARTIS	2.5MG	N022334	003	Jul 09, 2010	Jun	NEWA
	ZORTRESS						
	NOVARTIS	0.25MG	N021560	001	Apr 20, 2010	Apr	NEWA
		0.5MG	N021560	002	Apr 20, 2010	Apr	NEWA
	+	0.75MG	N021560	003	Apr 20, 2010	Apr	NEWA

FAMOTIDINE

FOR SUSPENSION; ORAL

	FAMOTIDINE								
>A>	AB	LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Jun	NEWA	
	AB	NAVINTA LLC	40MG/5ML	A091020	001	May 27, 2010	May	NEWA	
		PEPCID							
	AB	+	SALIX PHARMS	40MG/5ML	N019527	001	Feb 02, 1987	May	CFTG

INJECTABLE; INJECTION

	FAMOTIDINE								
	AP	+	BAXTER HLTHCARE	10MG/ML	A075799	001	Apr 30, 2002	Feb	CRLD
	AP	+		10MG/ML	A075488	001	Apr 16, 2001	Feb	CRLD

	FAMOTIDINE PRESERVATIVE FREE						
--	------------------------------	--	--	--	--	--	--

>D>	AP	APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Jun	CAHN	
	AP	+	BAXTER HLTHCARE	10MG/ML	A075789	001	Apr 30, 2002	Feb	CRLD

	AP	+		10MG/ML	A075486	001	Apr 16, 2001	Feb	CRLD
--	----	---	--	---------	---------	-----	--------------	-----	------

>A>	AP	CLARIS LIFESCIENCES	10MG/ML	A076324	001	Nov 27, 2002	Jun	CAHN
-----	----	---------------------	---------	---------	-----	--------------	-----	------

	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
--	--	--	--	--	--	--	--

>D>	AP	APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Jun	CAHN
-----	----	------------	---------	---------	-----	--------------	-----	------

>A>	AP	CLARIS LIFESCIENCES	10MG/ML	A076322	001	Nov 27, 2002	Jun	CAHN
-----	----	---------------------	---------	---------	-----	--------------	-----	------

	FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER						
--	---	--	--	--	--	--	--

	AP	+	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001	Feb	CRLD
--	----	---	-----------------	----------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

	FLUXID						
	@ SCHWARZ PHARMA	20MG	N021712	001	Sep 24, 2004	Jan	DISC
	@	40MG	N021712	002	Sep 24, 2004	Jan	DISC

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Jan	CAHN
@	87MG	N021695 002	Nov 30, 2004	Jan	CAHN
+	130MG	N021695 003	Nov 30, 2004	Jan	CAHN

TABLET; ORAL

FENOGLIDE

SHIONOGI PHARMA	40MG	N022118 001	Aug 10, 2007	Jan	CAHN
+	120MG	N022118 002	Aug 10, 2007	Jan	CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA D 24 HOUR

AB	+	SANOFI AVENTIS US	180MG;240MG	N021704 001	Oct 19, 2004	Mar	CFTG
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	180MG;240MG	A079043 001	Mar 17, 2010	Mar	NEWA

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB		ACCORD HLTHCARE INC	5MG	A090121 001	Feb 23, 2010	Feb	NEWA
AB		HETERO DRUGS LTD	5MG	A090061 001	Jun 07, 2010	May	NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	100MG	A076835 001	Nov 30, 2005	May	CAHN
----	--	-------------	-------	-------------	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

BEDFORD	100MG/50ML (2MG/ML)	A076087 002	Sep 26, 2008	Jan	CTNA		
AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077947 001	May 26, 2010	May	NEWA	
AP		400MG/200ML (2MG/ML)	A077947 002	May 26, 2010	May	NEWA	
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077909 001	May 26, 2010	May	NEWA	
AP		400MG/200ML (2MG/ML)	A077909 002	May 26, 2010	May	NEWA	
@	HOSPIRA	200MG/100ML (2MG/ML)	A076617 001	Jul 29, 2004	Feb	DISC	
@		400MG/200ML (2MG/ML)	A076617 002	Jul 29, 2004	Feb	DISC	
FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077988 001	May 26, 2010	May	NEWA	
AP		400MG/200ML (2MG/ML)	A077988 002	May 26, 2010	May	NEWA	

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

FEINSTEIN	20-300mCi/ML	N021870 002	Nov 21, 2008	May	NEWA
-----------	--------------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

>D>	AP	APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755 002	Oct 12, 2004	Jun	CAHN
>D>	AP		1MG/10ML (0.1MG/ML)	A076755 001	Oct 12, 2004	Jun	CAHN
>A>	AP	CLARIS LIFESCIENCES	0.5MG/5ML (0.1MG/ML)	A076755 002	Oct 12, 2004	Jun	CAHN

INJECTABLE; INJECTION

FLUMAZENIL

>A> AP CLARIS LIFESCIENCES 1MG/10ML (0.1MG/ML) A076755 001 Oct 12, 2004 Jun CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ ACTON PHARMS EQ 78MCG BASE/INH N021247 001 Jan 27, 2006 Feb CAHN

SPRAY, METERED; NASAL

FLUNISOLIDE

>D> AB APOTEX INC 0.029MG/SPRAY A077436 001 Aug 09, 2007 Jun CRLD

>A> + 0.029MG/SPRAY A077436 001 Aug 09, 2007 Jun CRLD

NASAREL

>D> AB + TEVA BRANDED PHARM 0.029MG/SPRAY N020409 001 Mar 08, 1995 Jun DISC

>A> @ 0.029MG/SPRAY N020409 001 Mar 08, 1995 Jun DISC

AB + 0.029MG/SPRAY N020409 001 Mar 08, 1995 Feb CAHN

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

AB TARO 5% A090368 001 Mar 05, 2010 Feb NEWA

INJECTABLE; INJECTION

FLUOROURACIL

AP + BIONICHE PHARMA 500MG/10ML (50MG/ML) A040743 002 Apr 26, 2007 Mar CAHN

AP + 1GM/20ML (50MG/ML) A040743 001 Apr 26, 2007 Mar CAHN

AP + 2.5GM/50ML (50MG/ML) A040798 002 Apr 26, 2007 Mar CAHN

AP + 5GM/100ML (50MG/ML) A040798 001 Apr 26, 2007 Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

AB BARR EQ 90MG BASE A076237 001 Mar 24, 2010 Mar NEWA

AB DR REDDYS LABS LTD EQ 90MG BASE A078572 001 Mar 22, 2010 Mar NEWA

PROZAC WEEKLY

AB + LILLY EQ 90MG BASE N021235 001 Feb 26, 2001 Mar CFTG

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA LANNETT EQ 20MG BASE/5ML A076458 001 May 14, 2004 Feb CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>D> AO APOTEX INC 25MG/ML A075918 001 Aug 17, 2001 Jun CAHN

>A> AO CLARIS LIFESCIENCES 25MG/ML A075918 001 Aug 17, 2001 Jun CAHN

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

>A> AB ANI PHARMS 25MG N021519 001 Dec 20, 2007 Jun CAHN

>A> AB 50MG N021519 002 Dec 20, 2007 Jun CAHN

>A> AB 100MG N021519 003 Dec 20, 2007 Jun CAHN

>D> AB JAZZ 25MG N021519 001 Dec 20, 2007 Jun CAHN

>D> AB 50MG N021519 002 Dec 20, 2007 Jun CAHN

>D> AB 100MG N021519 003 Dec 20, 2007 Jun CAHN

FOLIC ACID

TABLET; ORAL						
FOLIC ACID						
AA + PHARMAX	1MG	A040625 001	Jul 21, 2005	Jan	CRLD	
AA VINTAGE	1MG	A040756 001	Jun 04, 2010	May	NEWA	
AA + WATSON LABS	1MG	A080680 001		Jan	CMFD	

FOMEPIZOLE

INJECTABLE; INJECTION						
FOMEPIZOLE						
AP BIONICHE PHARMA USA	1.5GM/1.5ML (1GM/ML)	A079033 001	Apr 07, 2009	Mar	CAHN	

FORMOTEROL FUMARATE

SOLUTION; INHALATION						
PERFOROMIST						
+ DEY PHARMA	0.02MG/2ML	N022007 001	May 11, 2007	Apr	CAHN	

>A> FORMOTEROL FUMARATE; MOMETASONE FUROATE

>A> AEROSOL, METERED; INHALATION						
DULERA						
>A> + SCHERING	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	NEWA	
>A> +	0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	NEWA	

FOSCARNET SODIUM

INJECTABLE; INJECTION						
FOSCAVIR						
>D> AP + ASTRAZENECA	2.4GM/100ML	N020068 001	Sep 27, 1991	Jun	CAHN	
>A> AP + CLINIGEN HLTHCARE	2.4GM/100ML	N020068 001	Sep 27, 1991	Jun	CAHN	

FOSINOPRIL SODIUM

TABLET; ORAL						
FOSINOPRIL SODIUM						
>D> AB COBALT	10MG	A077531 001	Aug 31, 2006	Jun	CAHN	
>D> AB	20MG	A077531 002	Aug 31, 2006	Jun	CAHN	
>D> AB	40MG	A077531 003	Aug 31, 2006	Jun	CAHN	
>A> AB WATSON LABS	10MG	A077531 001	Aug 31, 2006	Jun	CAHN	
>A> AB	20MG	A077531 002	Aug 31, 2006	Jun	CAHN	
>A> AB	40MG	A077531 003	Aug 31, 2006	Jun	CAHN	

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION						
FOSPHENYTOIN SODIUM						
AP LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A090099 001	May 13, 2010	May	NEWA	
AP PHARMAFORCE	EQ 50MG PHENYTOIN NA/ML	A078277 001	Aug 06, 2007	Feb	CAHN	
AP STRIDES ARCOLAB	EQ 50MG PHENYTOIN NA/ML	A078736 001	Jun 08, 2010	May	NEWA	
>D> AP SUN PHARM INDs	EQ 50MG PHENYTOIN NA/ML	A078417 001	Mar 18, 2008	Jun	CAHN	
>A> AP SUN PHARMA GLOBAL	EQ 50MG PHENYTOIN NA/ML	A078417 001	Mar 18, 2008	Jun	CAHN	

GABAPENTIN

CAPSULE; ORAL						
GABAPENTIN						
@ SANDOZ	100MG	A075539 001	Apr 06, 2005	May	DISC	
@	300MG	A075539 002	Apr 06, 2005	May	DISC	
@	400MG	A075539 003	Apr 06, 2005	May	DISC	

TABLET; ORALGABAPENTIN

AB	MATRIX LABS LTD	600MG	A090335 001	Jun 01, 2010	May	NEWA
AB		800MG	A090335 002	Jun 01, 2010	May	NEWA
@	SANDOZ	600MG	A076877 001	Jul 06, 2006	May	DISC
@		800MG	A076877 002	Jul 06, 2006	May	DISC

GADOVERSETAMIDEINJECTABLE; INJECTIONOPTIMARK IN PLASTIC CONTAINER

+ MALLINCKRODT	9927MG/30ML (330.9MG/ML)	N020976 001	Dec 08, 1999	Mar	CPOT
----------------	--------------------------	-------------	--------------	-----	------

GANCICLOVIRGEL; OPHTHALMICZIRGAN

>A>	+ BAUSCH AND LOMB	0.15%	N022211 001	Sep 15, 2009	Jun	CAHN
>D>	+ SIRION THERAP	0.15%	N022211 001	Sep 15, 2009	Jun	CAHN

GANCICLOVIR SODIUMINJECTABLE; INJECTIONCYTOVENE

>D>	+ ROCHE PALO	EQ 500MG BASE/VIAL	N019661 001	Jun 23, 1989	Jun	CFTG
>A> AP	+ +	EQ 500MG BASE/VIAL	N019661 001	Jun 23, 1989	Jun	CFTG
	+ +	EQ 500MG BASE/VIAL	N019661 001	Jun 23, 1989	Mar	CMFD
>A>	GANCICLOVIR					
>A> AP	APP PHARMS	EQ 500MG BASE/VIAL	A090658 001	Jun 21, 2010	Jun	NEWA
	GANCICLOVIR SODIUM					
	@ BEDFORD	EQ 500MG BASE/VIAL	A076222 001	Jul 16, 2003	Mar	DISC

GATIFLOXACINSOLUTION/DROPS; OPHTHALMICZYMAXID

+ ALLERGAN	0.5%	N022548 001	May 18, 2010	May	NEWA
------------	------	-------------	--------------	-----	------

GEMFIBROZILTABLET; ORALGEMFIBROZIL

AB	DAVA PHARMS INC	600MG	A074270 001	Sep 27, 1993	Mar	CMFD
----	-----------------	-------	-------------	--------------	-----	------

GEMIFLOXACIN MESYLATETABLET; ORALFACTIVE

+ CORNERSTONE THERAP	EQ 320MG BASE	N021158 001	Apr 04, 2003	May	CAHN
----------------------	---------------	-------------	--------------	-----	------

GLIMEPIRIDETABLET; ORALGLIMEPIRIDE

>D> AB	COBALT	1MG	A077280 001	Feb 03, 2006	Jun	CAHN
>D> AB		2MG	A077280 002	Feb 03, 2006	Jun	CAHN
>D> AB		4MG	A077280 003	Feb 03, 2006	Jun	CAHN
>A> AB	WATSON LABS	1MG	A077280 001	Feb 03, 2006	Jun	CAHN
>A> AB		2MG	A077280 002	Feb 03, 2006	Jun	CAHN
>A> AB		4MG	A077280 003	Feb 03, 2006	Jun	CAHN
AB	WATSON LABS FLORIDA	1MG	A076995 001	Apr 27, 2010	Apr	NEWA
AB		2MG	A076995 002	Apr 27, 2010	Apr	NEWA
AB		4MG	A076995 003	Apr 27, 2010	Apr	NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>A>	AB	INDICUS PHARMA	2.5MG;250MG	A078728 001	Jun 23, 2010	Jun	NEWA
>A>	AB		2.5MG;500MG	A078728 002	Jun 23, 2010	Jun	NEWA
>A>	AB		5MG;500MG	A078728 003	Jun 23, 2010	Jun	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	TEVA		1.25MG;250MG	A076821 001	Jan 27, 2005	Jan	DISC
@			2.5MG;500MG	A076821 002	Jan 27, 2005	Jan	DISC
@			5MG;500MG	A076821 003	Jan 27, 2005	Jan	DISC

GLYCOPYRROLATE

TABLET; ORAL

ROBINUL

AA	+	SHIONOGI PHARMA	1MG	N012827 001		Jan	CAHN
		ROBINUL FORTE					
AA	+	SHIONOGI PHARMA	2MG	N012827 002		Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	APOTEX CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007	Jun	CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008	Jun	CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008	Jun	CAHN
>A>	AP	CLARIS LIFESCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007	Jun	CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008	Jun	CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008	Jun	CAHN
	AP	SAGENT STRIDES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A091136 001	Apr 09, 2010	Mar	NEWA
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091136 002	Apr 09, 2010	Mar	NEWA
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137 002	Apr 09, 2010	Mar	NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@	BARR		EQ 1MG BASE	A078221 001	Dec 31, 2007	May	DISC
AB	TARO		EQ 1MG BASE	A090817 001	May 28, 2010	May	NEWA

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

@	ELORAC		250MG	A060569 002		Feb	CAHN
@			500MG	A060569 001		Feb	CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB		MIKAH PHARMA	EQ 1MG BASE	A074673 001	Feb 28, 1997	Feb	CAHN
AB			EQ 2MG BASE	A074673 002	Feb 28, 1997	Feb	CAHN

HALCINONIDE

SOLUTION; TOPICAL
HALOG
@ RANBAXY 0.1%

N017823 001 May DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

>D>	AO	APOTEX INC	EQ 50MG BASE/ML	A075440 001	Feb 28, 2000	Jun	CAHN
>D>	AO		EQ 100MG BASE/ML	A075440 002	Feb 28, 2000	Jun	CAHN
>A>	AO	CLARIS LIFESCIENCES	EQ 50MG BASE/ML	A075440 001	Feb 28, 2000	Jun	CAHN
>A>	AO		EQ 100MG BASE/ML	A075440 002	Feb 28, 2000	Jun	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALDOL
@ ORTHO MCNEIL JANSSEN EQ 5MG BASE/ML
HALOPERIDOL

>D>	AP	APOTEX INC	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004	Jun	CAHN
>D>	AP		EQ 5MG BASE/ML	A076828 001	Aug 25, 2004	Jun	CAHN
>A>	AP	CLARIS LIFESCIENCES	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004	Jun	CAHN
>A>	AP		EQ 5MG BASE/ML	A076828 001	Aug 25, 2004	Jun	CAHN
	AP	+ TEVA PARENTERAL	EQ 5MG BASE/ML	A076035 001	Aug 29, 2001	Feb	CRLD

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

>A>	AP	SAGENT PHARMS	1,000 UNITS/ML	A090808 001	Jun 30, 2010	Jun	NEWA
>A>	AP		5,000 UNITS/ML	A090808 002	Jun 30, 2010	Jun	NEWA
>A>	AP		10,000 UNITS/ML	A090808 003	Jun 30, 2010	Jun	NEWA
>A>	AP		20,000 UNITS/ML	A090809 001	Jun 30, 2010	Jun	NEWA
		HEPARIN SODIUM PRESERVATIVE FREE					
		@ HOSPIRA	2,000 UNITS/ML	N005264 013	Apr 07, 1986	May	DISC
		@	2,500 UNITS/ML	N005264 014	Apr 07, 1986	May	DISC
>A>	AP	SAGENT PHARMS	1,000 UNITS/ML	A090810 001	Jun 30, 2010	Jun	NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL
CYSVIEW KIT
+ PHOTOCURE ASA 100MG/VIAL

N022555 001 May 28, 2010 May NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

AA	HERITAGE PHARMS INC	10MG	A086242 001	Feb 04, 2010	Jan	NEWA
AA		100MG	A086242 004	Feb 04, 2010	Jan	NEWA
AA	ZYDUS PHARMS USA	10MG	A040858 001	Feb 26, 2010	Feb	NEWA
AA		25MG	A040858 002	Feb 26, 2010	Feb	NEWA
AA		50MG	A040858 003	Feb 26, 2010	Feb	NEWA
AA		100MG	A040858 004	Feb 26, 2010	Feb	NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB	UNICHEM	12.5MG	A090510 001	Jan 19, 2010	Jan	NEWA
----	---------	--------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

@ TEVA	12.5MG;10MG
@	12.5MG;20MG
@	25MG;20MG

A075869 001	Jul 01, 2002	Jan	DISC
A075869 002	Jul 01, 2002	Jan	DISC
A075869 003	Jul 01, 2002	Jan	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

AB	MERCK	12.5MG;50MG
AB		12.5MG;100MG
AB	+	25MG;100MG

N020387 001	Apr 28, 1995	Mar	CFTG
N020387 003	Oct 20, 2005	Mar	CFTG
N020387 002	Nov 10, 1998	Mar	CFTG

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	12.5MG;100MG
AB	MYLAN	12.5MG;100MG
AB	ROXANE	12.5MG;100MG
AB	TEVA PHARMS	12.5MG;50MG
AB		12.5MG;100MG
AB		25MG;100MG
AB	TORRENT PHARMS	12.5MG;100MG

A078245 002	May 21, 2010	May	NEWA
A091652 002	Apr 06, 2010	Mar	NEWA
A077732 001	Apr 06, 2010	Mar	NEWA
A077157 001	Apr 06, 2010	Mar	NEWA
A077157 002	Apr 06, 2010	Mar	NEWA
A077157 003	Apr 06, 2010	Mar	NEWA
A090528 003	Apr 06, 2010	Mar	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;100MG
AB	+	25MG;100MG
		50MG;100MG

A076792 002	Aug 20, 2004	Apr	CRLD
A076792 002	Aug 20, 2004	Jan	CRLD
A076792 003	Aug 20, 2004	Jan	CTEC

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS	12.5MG;7.5MG
AB		12.5MG;15MG
AB		25MG;15MG

A090718 001	Mar 17, 2010	Mar	NEWA
A090718 002	Mar 17, 2010	Mar	NEWA
A090718 003	Mar 17, 2010	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

>D>	AB	+	GLAXOSMITHKLINE	25MG;37.5MG
>D>		@		25MG;50MG
>A>	AB	+	GLAXOSMITHKLINE LLC	25MG;37.5MG
>A>		@		25MG;50MG

N016042 003	Mar 03, 1994	Jun	CAHN
N016042 002		Jun	CAHN
N016042 003	Mar 03, 1994	Jun	CAHN
N016042 002		Jun	CAHN

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

>A>	AB		WATSON LABS FLORIDA	5MG;200MG
-----	----	--	---------------------	-----------

A077454 001	Jun 23, 2010	Jun	NEWA
-------------	--------------	-----	------

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA	1%
AT	+		2.5%

A080693 003		Feb	CRLD
A089414 001	Dec 16, 1986	Feb	CRLD

CREAM; TOPICAL

HYTONE

@ SANOFI AVENTIS US	1%	A080472 003	Feb	DISC
@	2.5%	A080472 004	Feb	DISC

LOTION; TOPICAL

HYDROCORTISONE

>D> AT	ALTANA	2.5%	A040351 001	Jul 25, 2000	Jun	CRLD
>A> AT	+	2.5%	A040351 001	Jul 25, 2000	Jun	CRLD

HYTONE

@ SANOFI AVENTIS US	1%	A080473 003	Feb	DISC	
@	2.5%	A080473 004	Nov 30, 1982	Feb	DISC

OINTMENT; TOPICAL

HYDROCORTISONE

>D> AT	ALTANA	1%	A080692 001		Jun	CRLD
>A> AT	+	1%	A080692 001		Jun	CRLD
>D> AT	FOUGERA	2.5%	A081203 001	May 28, 1993	Jun	CRLD
>A> AT	+	2.5%	A081203 001	May 28, 1993	Jun	CRLD

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP	AKORN	10MG/ML	A078228 001	Apr 14, 2010	Apr	NEWA
AP		10MG/ML	A078261 001	Apr 14, 2010	Mar	NEWA
AP		10MG/ML	A078228 001	Apr 14, 2010	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC	8MG	N021217 001	Mar 01, 2010	Mar	NEWA
	12MG	N021217 002	Mar 01, 2010	Mar	NEWA
+	16MG	N021217 003	Mar 01, 2010	Mar	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	HERITAGE PHARMS INC	10MG	A040804 001	Jun 30, 2008	May	CAHN
AB		25MG	A040804 002	Jun 30, 2008	May	CAHN
AB		50MG	A040804 003	Jun 30, 2008	May	CAHN
AB	MYLAN	10MG	A091176 001	Jun 07, 2010	May	NEWA
AB		25MG	A091176 002	Jun 07, 2010	May	NEWA
AB		50MG	A091176 003	Jun 07, 2010	May	NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761 001	Mar 05, 1982	Apr	DISC
@	EQ 50MG HCL	A087760 001	Mar 05, 1982	Apr	DISC

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	CONTRACT PHARMACAL	400MG	A071267 001	Oct 15, 1986	Jan	CAHN
AB		600MG	A071268 001	Oct 15, 1986	Jan	CAHN
AB		800MG	A072300 001	Jul 01, 1988	Jan	CAHN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

AP BIONICHE PHARMA USA 0.1MG/ML

A090924 001 Jan 11, 2010 Mar CAHN

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

AP BAXTER HLTHCARE 1GM/VIAL

N019763 001 Dec 30, 1988 Feb CMFD

AP 3GM/VIAL

N019763 002 Dec 30, 1988 Feb CMFD

IFOSFAMIDE

AP + APP PHARMS 1GM/VIAL

A076078 001 May 28, 2002 Feb CTEC

AP + 1GM/VIAL

A076078 001 May 28, 2002 Feb CTEC

+ 1GM/VIAL

A076078 001 May 28, 2002 Jan CTEC

+ 1GM/VIAL

A076078 001 May 28, 2002 Jan CTEC

AP 1GM/20ML (50MG/ML)

A090181 001 Sep 22, 2009 Jan CPOT

AP + 3GM/VIAL

A076078 002 May 28, 2002 Feb CTEC

AP + 3GM/VIAL

A076078 002 May 28, 2002 Feb CTEC

AP 3GM/60ML (50MG/ML)

A090181 002 Sep 22, 2009 Jan CPOT

+ 3GM/VIAL

A076078 002 May 28, 2002 Jan CTEC

+ 3GM/VIAL

A076078 002 May 28, 2002 Jan CTEC

AP + TEVA PARENTERAL 1GM/20ML (50MG/ML)

A076657 001 Apr 04, 2007 Jan CTEC

AP + 3GM/60ML (50MG/ML)

A076657 002 Apr 04, 2007 Jan CTEC

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

@ BAXTER HLTHCARE

1GM/VIAL;100MG/ML

N019763 003 Oct 10, 1992 Feb DISC

@

3GM/VIAL;100MG/ML

N019763 004 Oct 10, 1992 Feb DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB LUPIN LTD 10MG

A090443 001 Mar 11, 2010 Feb NEWA

AB 25MG

A090442 001 Mar 11, 2010 Feb NEWA

AB 50MG

A090441 001 Mar 11, 2010 Feb NEWA

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB LUPIN LTD EQ 75MG HCL

A090444 001 Apr 16, 2010 Apr NEWA

AB EQ 100MG HCL

A090444 002 Apr 16, 2010 Apr NEWA

AB EQ 125MG HCL

A090444 003 Apr 16, 2010 Apr NEWA

AB EQ 150MG HCL

A090444 004 Apr 16, 2010 Apr NEWA

AB ROXANE EQ 75MG HCL

A091099 001 Apr 16, 2010 Apr NEWA

AB EQ 100MG HCL

A091099 002 Apr 16, 2010 Apr NEWA

AB EQ 125MG HCL

A091099 003 Apr 16, 2010 Apr NEWA

AB EQ 150MG HCL

A091099 004 Apr 16, 2010 Apr NEWA

TOFRANIL-PM

AB + TYCO HLTHCARE EQ 75MG HCL

N017090 001 Apr CFTG

AB EQ 100MG HCL

N017090 004 Apr CFTG

AB EQ 125MG HCL

N017090 003 Apr CFTG

AB EQ 150MG HCL

N017090 002 Apr CFTG

IMIQUIMOD

CREAM; TOPICAL						
ALDARA						
AB + GRACEWAY	5%			N020723	001	Feb 27, 1997 Feb CFTG
IMIQUIMOD						
AB NYCOMED US	5%			A078548	001	Feb 25, 2010 Feb NEWA
ZYCLARA						
+ GRACEWAY	3.75%			N022483	001	Mar 25, 2010 Mar NEWA

INAMRINONE LACTATE

INJECTABLE; INJECTION						
AMRINONE LACTATE						
@ BAXTER HLTHCARE CORP	EQ 5MG BASE/ML			A075542	001	May 10, 2000 Feb DISC
+ BEDFORD	EQ 5MG BASE/ML			A075513	001	May 09, 2000 Feb CTEC

INDOMETHACIN

INJECTABLE; INJECTION						
INDOMETHACIN						
+ APP PHARMS	EQ 1MG BASE/VIAL			N022536	001	Mar 17, 2010 Mar NEWA

IOPAMIDOL

INJECTABLE; INJECTION						
>A> SCANLUX-300						
>A> AP SANOCHEMIA CORP USA	61%			A090394	001	Jun 18, 2010 Jun NEWA
>A> SCANLUX-370						
>A> AP SANOCHEMIA CORP USA	76%			A090394	002	Jun 18, 2010 Jun NEWA

IOVERSOL

INJECTABLE; INJECTION						
OPTIRAY 160						
@ MALLINCKRODT	34%			N019710	003	Dec 30, 1988 May DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION						
IRINOTECAN HYDROCHLORIDE						
AP DR REDDYS LABS LTD	40MG/2ML (20MG/ML)			A078953	001	Apr 15, 2010 Apr NEWA
AP	100MG/5ML (20MG/ML)			A078953	002	Apr 15, 2010 Apr NEWA
@ SANDOZ	40MG/2ML (20MG/ML)			A077994	001	Feb 27, 2008 Mar DISC
@	100MG/5ML (20MG/ML)			A077994	002	Feb 27, 2008 Mar DISC

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL						
ISOSORBIDE DINITRATE						
AB + CARACO	40MG			A040009	001	Dec 30, 1998 Mar CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION						
LYMPHAZURIN						
>A> + COVIDIEN	1%			N018310	001	Jun CAHN
>D> + US SURGCL	1%			N018310	001	Jun CAHN

ISRADIPIINE

CAPSULE; ORAL						
ISRADIPIINE						
>D> AB COBALT LABS INC	2.5MG			A077317	001	Jan 05, 2006 Jun CAHN

CAPSULE; ORALISRADIPINE

>D>	AB	+	COBALT LABS INC	5MG	A077317 002	Jan 05, 2006	Jun	CAHN
>A>	AB		WATSON LABS	2.5MG	A077317 001	Jan 05, 2006	Jun	CAHN
>A>	AB	+		5MG	A077317 002	Jan 05, 2006	Jun	CAHN

TABLET, EXTENDED RELEASE; ORALDYNACIRC CR

>A>			GLAXOSMITHKLINE LLC	5MG	N020336 001	Jun 01, 1994	Jun	CAHN
>A>		+		10MG	N020336 002	Jun 01, 1994	Jun	CAHN
>D>			SMITHKLINE BEECHAM	5MG	N020336 001	Jun 01, 1994	Jun	CAHN
>D>		+		10MG	N020336 002	Jun 01, 1994	Jun	CAHN

ITRACONAZOLETABLET; ORALITRACONAZOLE

+	STIEFEL LABS INC	200MG	N022484 001	Apr 29, 2010	Apr	NEWA
---	------------------	-------	-------------	--------------	-----	------

KETOROLAC TROMETHAMINEINJECTABLE; INJECTIONKETOROLAC TROMETHAMINE

>D>	AP		APOTEX INC	15MG/ML	A075631 002	Jun 29, 2001	Jun	CAHN
>D>	AP			30MG/ML	A075631 001	Jun 29, 2001	Jun	CAHN
>A>	AP		CLARIS LIFESCIENCES	15MG/ML	A075631 002	Jun 29, 2001	Jun	CAHN
>A>	AP			30MG/ML	A075631 001	Jun 29, 2001	Jun	CAHN

SPRAY, METERED; NASALSPRIX

+	ROXRO PHARMA INC	15.75MG/SPRAY	N022382 001	May 14, 2010	May	NEWA
---	------------------	---------------	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTIONLABETALOL HYDROCHLORIDE

>D>	AP		APOTEX INC	5MG/ML	A076051 001	Jul 05, 2002	Jun	CAHN
>A>	AP		CLARIS LIFESCIENCES	5MG/ML	A076051 001	Jul 05, 2002	Jun	CAHN
			LABETALOL HYDROCHLORIDE					
	AP		SAGENT STRIDES	5MG/ML	A079134 001	Feb 03, 2010	Jan	NEWA

TABLET; ORALTRANDATE

AB	+	PROMETHEUS LABS	200MG	N018716 002	Aug 01, 1984	Feb	CRLD
	@		300MG	N018716 003	Aug 01, 1984	Apr	DISC
AB			300MG	N018716 003	Aug 01, 1984	Feb	CRLD

LACOSAMIDESOLUTION; ORALVIMPAT

+	SCHWARZ BIOSCIENCES	10MG/ML	N022255 001	Apr 20, 2010	Apr	NEWA
---	---------------------	---------	-------------	--------------	-----	------

LAMOTRIGINETABLET; ORALLAMOTRIGINE

AB		LUPIN LTD	25MG	A078691 001	Jun 01, 2010	May	NEWA
AB			100MG	A078691 002	Jun 01, 2010	May	NEWA
AB			150MG	A078691 003	Jun 01, 2010	May	NEWA
AB			200MG	A078691 004	Jun 01, 2010	May	NEWA

TABLET, CHEWABLE; ORALLAMOTRIGINE

>D>	AB		COBALT LABS INC	2MG	A076928 001	Jan 22, 2009	Jun	CAHN
-----	----	--	-----------------	-----	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL
LEVONORGESTREL
AB + WATSON LABS 0.75MG A078665 001 Aug 28, 2009 Apr CRLD

LEVOTHYROXINE SODIUM

CAPSULE; ORAL
TIROSINT
INST BIOCHIMIQUE 0.013MG N022121 001 Aug 01, 2007 Feb CMFD
0.025MG N021924 002 Oct 13, 2006 Feb CMFD
0.05MG N021924 003 Oct 13, 2006 Feb CMFD
0.075MG N021924 004 Oct 13, 2006 Feb CMFD
0.088MG N021924 010 Oct 02, 2009 Feb NEWA
0.1MG N021924 005 Oct 13, 2006 Feb CMFD
0.112MG N021924 008 Oct 02, 2009 Feb NEWA
0.125MG N021924 006 Oct 13, 2006 Feb CMFD
0.137MG N021924 009 Oct 02, 2009 Feb NEWA
0.15MG N021924 007 Oct 13, 2006 Feb CMFD

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
LIDOCAINE AND PRILOCAINE
AB NYCOMED US 2.5%;2.5% A076453 001 Aug 18, 2003 Mar CAHN

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS
VICTOZA
+ NOVO NORDISK INC 18MG/3ML (6MG/ML) N022341 001 Jan 25, 2010 Jan NEWA

LISINOPRIL

TABLET; ORAL
LISINOPRIL
@ TEVA 2.5MG A075783 001 Jul 01, 2002 Jan DISC
@ 5MG A075783 002 Jul 01, 2002 Jan DISC
@ 10MG A075783 003 Jul 01, 2002 Jan DISC
@ 20MG A075783 004 Jul 01, 2002 Jan DISC
@ 30MG A075783 005 Jul 01, 2002 Jan DISC
@ 40MG A075783 006 Jul 01, 2002 Jan DISC

LITHIUM CARBONATE

CAPSULE; ORAL
ESKALITH
@ NOVEN THERAP 300MG N016860 001 Jan DISC
TABLET; ORAL
LITHIUM CARBONATE
>D> + ROXANE 300MG N018558 001 Jan 29, 1982 Jun CTEC
>A> AB + 300MG N018558 001 Jan 29, 1982 Jun CTEC
>A> AB SUN PHARM INDs INC 300MG A091027 001 Jun 24, 2010 Jun NEWA

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM
AA PHARM ASSOC 2MG/ML A090260 001 Jun 15, 2010 May NEWA

TABLET; ORAL

LORAZEPAM

>A>	AB	AMNEAL PHARMS	0.5MG	A078826	001	Jun 23,	2010	Jun	NEWA
>A>	AB		1MG	A078826	002	Jun 23,	2010	Jun	NEWA
>A>	AB		2MG	A078826	003	Jun 23,	2010	Jun	NEWA

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

AB	MERCK	25MG	N020386	001	Apr 14,	1995	Mar	CFTG
AB		50MG	N020386	002	Apr 14,	1995	Mar	CFTG
AB	+	100MG	N020386	003	Oct 13,	1998	Mar	CFTG
	LOSARTAN POTASSIUM							
AB	TEVA	25MG	A076958	001	Apr 06,	2010	Mar	NEWA
AB		50MG	A076958	002	Apr 06,	2010	Mar	NEWA
AB		100MG	A076958	003	Apr 06,	2010	Mar	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	PFIZER	50MG	N010721	001	Jan 20,	1982	Jan	CMFD
		MECLIZINE HYDROCHLORIDE							
AA	CADISTA PHARMS	12.5MG	A040659	001	Jun 04,	2010	May	NEWA	
AA		25MG	A040659	002	Jun 04,	2010	May	NEWA	

TABLET, CHEWABLE; ORAL

ANTIVERT

@ PFIZER

25MG

N010721 005

Jan DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

AB	WEST WARD	250MG	A077699	001	Apr 21,	2010	Apr	NEWA
----	-----------	-------	---------	-----	---------	------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP	BIONICHE PHARMA USA	EQ 50MG BASE/VIAL	A090299	001	Oct 27,	2009	Mar	CAHN
----	---------------------	-------------------	---------	-----	---------	------	-----	------

MEMANTINE HYDROCHLORIDE

>A> CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

>A>	FOREST LABS	7MG	N022525	001	Jun 21,	2010	Jun	NEWA
>A>		14MG	N022525	002	Jun 21,	2010	Jun	NEWA
>A>		21MG	N022525	003	Jun 21,	2010	Jun	NEWA
>A>	+	28MG	N022525	004	Jun 21,	2010	Jun	NEWA

TABLET; ORAL

MEMANTINE

@ SUN PHARM INDs (IN) 5MG

A090058 001 May 05, 2010 Apr DISC

@ 10MG

A090058 002 May 05, 2010 Apr DISC

MEMANTINE HYDROCHLORIDE

@ DR REDDYS LABS LTD 5MG

A090048 001 Apr 14, 2010 Apr DISC

5MG

A090048 001 Apr 14, 2010 Mar NEWA

@ 10MG

A090048 002 Apr 14, 2010 Apr DISC

10MG

A090048 002 Apr 14, 2010 Mar NEWA

NAMENDA

FOREST LABS 5MG

N021487 001 Oct 16, 2003 Apr CTEC

TABLET; ORAL

NAMENDA

AB	FOREST LABS	5MG	N021487 001	Oct 16, 2003	Mar	CFTG
	+	10MG	N021487 002	Oct 16, 2003	Apr	CTEC
AB	+	10MG	N021487 002	Oct 16, 2003	Mar	CFTG

MEPERIDINE HYDROCHLORIDE

SYRUP; ORAL

DEMEROL

@ SANOFI AVENTIS US	50MG/5ML	N005010 005	May	DISC	
+ ROXANE	50MG/5ML	A088744 001	Jan 30, 1985	Feb	CRLD

TABLET; ORAL

DEMEROL

AA	+ SANOFI AVENTIS US	50MG	N005010 001	May	CMFD	
	@	50MG	N005010 001	Feb	DISC	
	MEPERIDINE HYDROCHLORIDE					
AA	MIKAH PHARMA	50MG	A040331 001	May 28, 1999	Feb	CAHN
AA		100MG	A040331 002	May 28, 1999	Feb	CAHN

MEROPENEM

INJECTABLE; INJECTION

>A>	MEROPENEM					
>A>	AP HOSPIRA INC	500MG/VIAL	A090940 001	Jun 22, 2010	Jun	NEWA
>A>	AP	1GM/VIAL	A090940 002	Jun 22, 2010	Jun	NEWA
	MERREM I.V.					
>D>	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Jun	CFTG
>A>	AP +	500MG/VIAL	N050706 003	Jun 21, 1996	Jun	CFTG
>D>	+	1GM/VIAL	N050706 001	Jun 21, 1996	Jun	CFTG
>A>	AP +	1GM/VIAL	N050706 001	Jun 21, 1996	Jun	CFTG

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@ AXCAN	500MG	N021252 001	Jan 05, 2001	May	CAHN
+	1GM	N021252 002	Nov 05, 2004	May	CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL

+ WARNER CHILCOTT INC	400MG	N019651 001	Jan 31, 1992	Feb	CAHN
ASACOL HD					
+ WARNER CHILCOTT INC	800MG	N021830 001	May 29, 2008	Feb	CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	SAGENT STRIDES	100MG/ML	A090913 001	Apr 13, 2010	Mar	NEWA
----	----------------	----------	-------------	--------------	-----	------

METAXALONE

TABLET; ORAL

METAXALONE

AB	SANDOZ	800MG	A040445 001	Mar 31, 2010	Mar	NEWA
	SKELAXIN					
AB	+ KING PHARMS	800MG	N013217 003	Aug 30, 2002	Mar	CFTG

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	GRANULES INDIA	500MG	A090564 001	Apr 22, 2010	Apr	NEWA	
AB		850MG	A090564 002	Apr 22, 2010	Apr	NEWA	
AB		1GM	A090564 003	Apr 22, 2010	Apr	NEWA	
	@ IPCA LABS LTD	500MG	A078422 001	Aug 06, 2007	Mar	DISC	
	@	850MG	A078422 002	Aug 06, 2007	Mar	DISC	
	@	1GM	A078422 003	Aug 06, 2007	Mar	DISC	
	@ IVAX SUB TEVA PHARMS	500MG	A075975 001	Jan 24, 2002	Apr	DISC	
	@	625MG	A075975 004	Jan 24, 2002	Apr	DISC	
		625MG	A075972 005	Jan 24, 2002	Apr	CTEC	
	@	750MG	A075975 005	Jan 24, 2002	Apr	DISC	
		750MG	A075972 004	Jan 24, 2002	Apr	CTEC	
	@	850MG	A075975 002	Jan 24, 2002	Apr	DISC	
	@	1GM	A075975 003	Jan 24, 2002	Apr	DISC	
	TABLET, EXTENDED RELEASE; ORAL						
	METFORMIN HYDROCHLORIDE						
>D>	AB	COBALT	500MG	A076818 001	Dec 14, 2004	Jun	CAHN
		@ IVAX SUB TEVA PHARMS	500MG	A076545 001	Dec 01, 2003	Apr	DISC
	AB	TORRENT PHARMS	750MG	A079226 001	Feb 18, 2010	Jan	NEWA
>A>	AB	WATSON LABS	500MG	A076818 001	Dec 14, 2004	Jun	CAHN

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+ BIONICHE PHARMA 10MG/ML

N021624 001 Mar CAHN

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

>D>	+ ROXANE	5MG/5ML	A087393 001	Jun	CTEC	
>A>	AA +	5MG/5ML	A087393 001	Jun	CTEC	
>D>	+	10MG/5ML	A087997 001	Aug 30, 1982	Jun	CTEC
>A>	AA +	10MG/5ML	A087997 001	Aug 30, 1982	Jun	CTEC
>A>	AA VISTAPHARM	5MG/5ML	A090707 001	Jun 30, 2010	Jun	NEWA
>A>	AA	10MG/5ML	A090707 002	Jun 30, 2010	Jun	NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AA	+ LUNDBECK INC	5MG	N005378 002	Apr	CTEC	
AA	METHAMPHETAMINE HYDROCHLORIDE COASTAL PHARMS	5MG	A091189 001	Apr 21, 2010	Apr	NEWA

METHENAMINE HIPPURATE

TABLET; ORAL

UREX

AB	CNTY LINE PHARMS	1GM	N016151 001	Feb	CAHN
----	------------------	-----	-------------	-----	------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ BIONICHE PHARMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Mar	CAHN
AP	+ BIONICHE PHARMA USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768 001	Apr 30, 2007	Mar	CAHN

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP + BIONICHE PHARMA USA EQ 1GM BASE/40ML (EQ 25MG
BASE/ML) A040716 001 Apr 30, 2007 Mar CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@ HOSPIRA EQ 5MG BASE/ML A074147 001 Aug 02, 1996 Feb DISC

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ INTERPHARM EQ 10MG BASE A071213 001 Sep 24, 1986 May CAHN

@ SANDOZ EQ 10MG BASE A074478 002 Oct 05, 1995 Jan DISC

@ WATSON LABS EQ 10MG BASE A070511 001 Jan 22, 1986 Jan DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB WATSON LABS FLORIDA EQ 100MG TARTRATE A077298 001 Apr 15, 2010 Apr NEWA
AB EQ 200MG TARTRATE A077298 002 Apr 15, 2010 Apr NEWA

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP SAGENT STRIDES 1MG/ML A090317 001 Apr 19, 2010 Apr NEWA

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

@ IVAX SUB TEVA PHARMS 250MG N018517 001 Apr DISC

@ 500MG N018517 002 May 05, 1982 Apr DISC

@ WORLD GEN 250MG A070040 001 Jan 29, 1985 Mar CAHN

@ 500MG A070039 001 Jan 29, 1985 May CAHN

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

AB + GD SEARLE LLC 750MG N020868 001 Nov 26, 1997 Apr CFTG

METRONIDAZOLE

AB ALEMBIC LTD 750MG A090222 001 May 05, 2010 Apr NEWA

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ BIOALLIANCE PHARMA 50MG N022404 001 Apr 16, 2010 Apr NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP APOTEX INC	EQ 1MG BASE/ML	A075637 001 Oct 31, 2000 Jun CAHN
>D>	AP	EQ 5MG BASE/ML	A075637 002 Oct 31, 2000 Jun CAHN
>A>	AP CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637 001 Oct 31, 2000 Jun CAHN
>A>	AP	EQ 5MG BASE/ML	A075637 002 Oct 31, 2000 Jun CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>D>	AP APOTEX INC	EQ 1MG BASE/ML	A076427 001 Sep 21, 2004 Jun CAHN
-----	---------------	----------------	-----------------------------------

INJECTABLE; INJECTION

MILRINONE LACTATE

>A>	AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A076427 001	Sep 21, 2004	Jun	CAHN
MILRINONE LACTATE IN DEXTROSE 5%							
>D>	AP	APOTEX INC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151 002	Jul 20, 2005	Jun	CAHN
>A>	AP	CLARIS LIFESCIENCES	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151 002	Jul 20, 2005	Jun	CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	AP	APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151 001	Jul 20, 2005	Jun	CAHN
AP	+	BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075834 001	May 28, 2002	Feb	CTEC
AP	+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075834 002	May 28, 2002	Feb	CRLD
>A>	AP	CLARIS LIFESCIENCES	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151 001	Jul 20, 2005	Jun	CAHN
MILRINONE LACTATE IN PLASTIC CONTAINER							
AP		HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A090038 001	Jan 21, 2010	Jan	NEWA
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038 002	Jan 21, 2010	Jan	NEWA
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER							
@	SANOFI AVENTIS US		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343 003	Aug 09, 1994	Feb	DISC
@			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343 004	Aug 09, 1994	Feb	DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		BIONICHE PHARMA USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980 001	Apr 13, 2009	Mar	CAHN
AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980 002	Apr 13, 2009	Mar	CAHN

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

+ PISGAH LABS		EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	May	CAHN
---------------	--	----------------	-------------	--------------	-----	------

MOXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOXIPRIL HYDROCHLORIDE

AB		GLENMARK GENERICS	7.5MG	A090416 001	Mar 30, 2010	Mar	NEWA
AB			15MG	A090416 002	Mar 30, 2010	Mar	NEWA

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOBAN

@ ENDO PHARMS		5MG	N017111 004	May	DISC
@		10MG	N017111 005	May	DISC
@		25MG	N017111 006	May	DISC
@		50MG	N017111 007	May	DISC

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

>A>		EKR THERAP	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	Jun	CAHN
>A>	+		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	Jun	CAHN
>A>	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

>D>	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	Jun	CAHN
>D>	+	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	Jun	CAHN
>D>	@	20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	Jun	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

	ROXANE	20MG/5ML	N022195 002	Mar 17, 2008	Jan	CRLD
+		100MG/5ML	N022195 003	Jan 25, 2010	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

	@ PURDUE PHARMA LP	15MG	A074862 001	Jul 07, 1998	Feb	CAHN
	@	30MG	A074862 002	Jul 07, 1998	Feb	CAHN
	@	60MG	A074862 003	Jul 07, 1998	Feb	CAHN
	@	100MG	A074769 001	Jul 02, 1998	Feb	CAHN
	@	200MG	A074769 002	Jul 02, 1998	Feb	CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB	STRIDES ARCOLAB LTD	250MG	A090055 001	Jun 10, 2010	May	NEWA
----	---------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB	STRIDES ARCOLAB LTD	500MG	A090456 001	Jun 10, 2010	May	NEWA
----	---------------------	-------	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

>A>	AB	MATRIX LABS LTD	500MG	A090516 001	Jul 12, 2010	Jun	NEWA
>A>	AB		750MG	A090516 002	Jul 12, 2010	Jun	NEWA

NALIDIXIC ACID

TABLET; ORAL

NEGRAM

	@ SANOFI AVENTIS US	250MG	N014214 002		Feb	DISC
	@	500MG	N014214 004		Feb	DISC
	@	1GM	N014214 005		Feb	DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	+	WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736 001	Jan 21, 1997	Feb	CRLD
		TALWIN NX					
	@	SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733 001	Dec 16, 1982	Feb	DISC

NARatriptan Hydrochloride

TABLET; ORAL

AMERGE

>D>		GLAXOSMITHKLINE	EQ 1MG BASE	N020763 002	Feb 10, 1998	Jun	CFTG
>A>	AB		EQ 1MG BASE	N020763 002	Feb 10, 1998	Jun	CFTG
>D>	+		EQ 2.5MG BASE	N020763 001	Feb 10, 1998	Jun	CFTG
>A>	AB	+	EQ 2.5MG BASE	N020763 001	Feb 10, 1998	Jun	CFTG

NARatriptan

>A>	AB	PADDOCK LABS	EQ 1MG BASE	A091326 001	Jul 08, 2010	Jun	NEWA
>A>	AB		EQ 2.5MG BASE	A091326 002	Jul 08, 2010	Jun	NEWA
>A>	AB	ROXANE	EQ 1MG BASE	A090381 001	Jul 07, 2010	Jun	NEWA

TABLET; ORAL

NARatriptan

>A>	AB	ROXANE	EQ 2.5MG BASE	A090381	002	Jul 07, 2010	Jun	NEWA
>A>	AB	SANDOZ	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun	NEWA
>A>	AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun	NEWA
>A>	AB	TEVA PHARMS	EQ 1MG BASE	A078751	001	Jul 07, 2010	Jun	NEWA
>A>	AB		EQ 2.5MG BASE	A078751	002	Jul 07, 2010	Jun	NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	IVAX SUB TEVA PHARMS	50MG	A075763	001	Sep 16, 2003	Apr	DISC
@		100MG	A075763	002	Sep 16, 2003	Apr	DISC
@		150MG	A075763	003	Sep 16, 2003	Apr	DISC
@		200MG	A075763	004	Sep 16, 2003	Apr	DISC
@		250MG	A075763	005	Sep 16, 2003	Apr	DISC

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA	OMAN PHARM PRODUCTS	500MG	A065468	001	Mar 29, 2010	Mar	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

NICARDIPIINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPIINE HYDROCHLORIDE

AP	BIONICHE PHARMA USA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Mar	CAHN	
>A>	AP	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Jun	CAHN
>D>	AP	SUN PHARM IND'S INC	25MG/10ML (2.5MG/ML)	A078405	001	Nov 17, 2009	Jun	CAHN
>A>	AP	SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	A078405	001	Nov 17, 2009	Jun	CAHN
>D>	AP	TEVA PARENTERAL	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Jun	CAHN

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	INTERGEL PHARM	10MG	A072781	001	Jul 30, 1993	Mar	CAHN
----	----------------	------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

>A>	AB2	MYLAN	30MG	A090649	001	Jun 21, 2010	Jun	NEWA
>A>	AB2		60MG	A090649	002	Jun 21, 2010	Jun	NEWA
>A>	AB2		90MG	A090649	003	Jun 21, 2010	Jun	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CAHN
@		10MG	N020356	001	Feb 02, 1995	Jan	CAHN
+		17MG	N020356	007	Jan 02, 2008	Jan	CAHN
@		20MG	N020356	002	Feb 02, 1995	Jan	CAHN
		25.5MG	N020356	006	Jan 02, 2008	Jan	CAHN
@		30MG	N020356	003	Feb 02, 1995	Jan	CAHN
+		34MG	N020356	005	Jan 02, 2008	Jan	CAHN
@		40MG	N020356	004	Feb 02, 1995	Jan	CAHN

NITROFURANTOIN

SUSPENSION; ORAL
 FURADANTIN
 + SHIONOGI PHARMA 25MG/5ML N009175 001 Jan CAHN

NITROGLYCERIN

AEROSOL; SUBLINGUAL
 NITROLINGUAL
 @ POHL BOSKAMP 0.4MG/SPRAY N018705 001 Oct 31, 1985 Mar CAHN
 @ SHIONOGI PHARMA 0.4MG/SPRAY N018705 001 Oct 31, 1985 Jan CAHN
 AEROSOL, METERED; SUBLINGUAL
 NITROMIST
 >D> + AKRIMAX PHARMS 0.4MG/SPRAY N021780 001 Nov 02, 2006 Jun CAHN
 >A> + NOVADEL 0.4MG/SPRAY N021780 001 Nov 02, 2006 Jun CAHN
 SPRAY, METERED; SUBLINGUAL
 NITROLINGUAL PUMPSPRAY
 + POHL BOSKAMP 0.4MG/SPRAY N018705 002 Jan 10, 1997 Mar CAHN
 + SHIONOGI PHARMA 0.4MG/SPRAY N018705 002 Jan 10, 1997 Jan CAHN

NORETHINDRONE

TABLET; ORAL-28
 HEATHER
 AB1 GLENMARK GENERICS 0.35MG A090454 001 Apr 23, 2010 Apr NEWA

OFLOXACIN

TABLET; ORAL
 OFLOXACIN
 @ LARKEN LABS 200MG A076093 001 Sep 02, 2003 Jan CAHN
 @ 300MG A076093 002 Sep 02, 2003 Jan CAHN
 @ 400MG A076093 003 Sep 02, 2003 Jan CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL
 OMEPRAZOLE AND SODIUM BICARBONATE
 AB PAR PHARM 20MG;1.1GM A078966 001 May 25, 2010 May NEWA
 AB 40MG;1.1GM A078966 002 May 25, 2010 May NEWA
 ZEGERID
 AB SANTARUS 20MG;1.1GM N021849 001 Feb 27, 2006 May CFTG
 AB + 40MG;1.1GM N021849 002 Feb 27, 2006 May CFTG

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
 ONDANSETRON
 AB AUROBINDO PHARMA 4MG A090469 001 Apr 12, 2010 Mar NEWA
 AB 8MG A090469 002 Apr 12, 2010 Mar NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
 ONDANSETRON HYDROCHLORIDE
 AP EMCURE PHARMS EQ 2MG BASE/ML A090424 001 Apr 16, 2010 Apr NEWA
 AP LANNETT EQ 2MG BASE/ML A090116 001 Apr 14, 2010 Mar NEWA

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE

AB	GAVIS PHARMS	100MG	A040284 001 Jun 19, 1998 Feb CAHN
----	--------------	-------	-----------------------------------

OXALIPLATIN

INJECTABLE; INJECTION

OXALIPLATIN

AP	+	HOSPIRA INC	50MG/VIAL	A078815 001 Sep 30, 2009 Jan CRLD
----	---	-------------	-----------	-----------------------------------

AP	+		100MG/VIAL	A078815 002 Sep 30, 2009 Jan CRLD
----	---	--	------------	-----------------------------------

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP		APP PHARMS	50MG/VIAL	A078819 001 Jun 02, 2010 May NEWA
----	--	------------	-----------	-----------------------------------

AP			100MG/VIAL	A078819 002 Jun 02, 2010 May NEWA
----	--	--	------------	-----------------------------------

AP		FRESENIUS KABI ONCOL	50MG/10ML (5MG/ML)	A078811 001 Jun 10, 2010 May NEWA
----	--	----------------------	--------------------	-----------------------------------

AP			100MG/20ML (5MG/ML)	A078811 002 Jun 10, 2010 May NEWA
----	--	--	---------------------	-----------------------------------

AP	+	HOSPIRA INC	50MG/VIAL	A078815 001 Sep 30, 2009 Apr CDFR
----	---	-------------	-----------	-----------------------------------

AP	+		100MG/VIAL	A078815 002 Sep 30, 2009 Apr CDFR
----	---	--	------------	-----------------------------------

>D>	AP	SUN PHARM INDs LTD	50MG/VIAL	A078818 001 Aug 07, 2009 Jun CAHN
-----	----	--------------------	-----------	-----------------------------------

>D>	AP		100MG/VIAL	A078818 002 Aug 07, 2009 Jun CAHN
-----	----	--	------------	-----------------------------------

>A>	AP	SUN PHARMA GLOBAL	50MG/VIAL	A078818 001 Aug 07, 2009 Jun CAHN
-----	----	-------------------	-----------	-----------------------------------

>A>	AP		100MG/VIAL	A078818 002 Aug 07, 2009 Jun CAHN
-----	----	--	------------	-----------------------------------

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

AB	CADISTA PHARMS	150MG	A090239 001 Jan 25, 2010 Jan NEWA
----	----------------	-------	-----------------------------------

AB		300MG	A090239 002 Jan 25, 2010 Jan NEWA
----	--	-------	-----------------------------------

AB		600MG	A090239 003 Jan 25, 2010 Jan NEWA
----	--	-------	-----------------------------------

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HYDROCHLORIDE

@	MALLINCKRODT	10MG	A077822 001 Jul 24, 2008 Apr DISC
---	--------------	------	-----------------------------------

@		20MG	A077822 002 Jul 24, 2008 Apr DISC
---	--	------	-----------------------------------

@		40MG	A077822 003 Jul 24, 2008 Apr DISC
---	--	------	-----------------------------------

@		80MG	A077822 004 Jul 24, 2008 Apr DISC
---	--	------	-----------------------------------

OXYCONTIN

>D>	PURDUE PHARMA INC	10MG	N022272 001 Apr 05, 2010 Jun DISC
-----	-------------------	------	-----------------------------------

		10MG	N022272 001 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>D>		15MG	N022272 002 Apr 05, 2010 Jun DISC
-----	--	------	-----------------------------------

		15MG	N022272 002 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>D>		20MG	N022272 003 Apr 05, 2010 Jun DISC
-----	--	------	-----------------------------------

		20MG	N022272 003 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>D>		30MG	N022272 004 Apr 05, 2010 Jun DISC
-----	--	------	-----------------------------------

		30MG	N022272 004 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>D>		40MG	N022272 005 Apr 05, 2010 Jun DISC
-----	--	------	-----------------------------------

		40MG	N022272 005 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>D>		60MG	N022272 006 Apr 05, 2010 Jun DISC
-----	--	------	-----------------------------------

		60MG	N022272 006 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>D>		80MG	N022272 007 Apr 05, 2010 Jun DISC
-----	--	------	-----------------------------------

		80MG	N022272 007 Apr 05, 2010 May NEWA
--	--	------	-----------------------------------

>A>	PURDUE PHARMA LP	10MG	N022272 001 Apr 05, 2010 Jun DISC
-----	------------------	------	-----------------------------------

		10MG	N020553 001 Dec 12, 1995 Apr CTEC
--	--	------	-----------------------------------

		10MG	N020553 001 Dec 12, 1995 Apr CTEC
--	--	------	-----------------------------------

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

>A>	@ PURDUE PHARMA LP	15MG	N022272 002	Apr 05, 2010	Jun	DISC
>A>	@	20MG	N022272 003	Apr 05, 2010	Jun	DISC
		20MG	N020553 002	Dec 12, 1995	Apr	CTEC
		20MG	N020553 002	Dec 12, 1995	Apr	CTEC
>A>	@	30MG	N022272 004	Apr 05, 2010	Jun	DISC
>A>	@	40MG	N022272 005	Apr 05, 2010	Jun	DISC
	+	40MG	N020553 003	Dec 12, 1995	Apr	CTEC
	+	40MG	N020553 003	Dec 12, 1995	Apr	CTEC
>A>	@	60MG	N022272 006	Apr 05, 2010	Jun	DISC
>A>	@	80MG	N022272 007	Apr 05, 2010	Jun	DISC
		80MG	N020553 004	Jan 06, 1997	Apr	CTEC
		80MG	N020553 004	Jan 06, 1997	Apr	CTEC

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

AB	ENDO PHARMS	5MG	N021610 001	Jun 22, 2006	May	CFTG
AB		10MG	N021610 002	Jun 22, 2006	May	CFTG
AB		20MG	N021610 003	Jun 22, 2006	May	CFTG
AB	+	40MG	N021610 004	Jun 22, 2006	May	CFTG
OXYMORPHONE HYDROCHLORIDE						
AB	IMPAK LABS	5MG	A079087 001	Jun 14, 2010	May	NEWA
AB		10MG	A079087 003	Jun 14, 2010	May	NEWA
AB		20MG	A079087 005	Jun 14, 2010	May	NEWA
AB		40MG	A079087 007	Jun 14, 2010	May	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL
@ PLIVA LACHEMA 6MG/ML A077413 001 Mar 12, 2008 Apr DISC

PALIPIERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

+ JOHNSON AND JOHNSON 234MG/1.5ML (156MG/ML) N022264 005 Jul 31, 2009 Jan CRLD

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM									
MN PHARMS	30MG/VIAL		A078300	001	Mar 10, 2009	Feb	CAHN		
	90MG/VIAL		A078300	002	Mar 10, 2009	Feb	CAHN		
SUN PHARM INDS	30MG/VIAL		A077703	001	Dec 24, 2008	Jun	CAHN		
	90MG/VIAL		A077703	002	Dec 24, 2008	Jun	CAHN		
SUN PHARMA GLOBAL	30MG/VIAL		A077703	001	Dec 24, 2008	Jun	CAHN		
	90MG/VIAL		A077703	002	Dec 24, 2008	Jun	CAHN		

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL
CREON

ABBOTT PRODS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Mar	CAHN
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Mar	CAHN
+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Mar	CAHN

CAPSULE, DELAYED RELEASE; ORALPANCREAZE

ORTHO MCNEIL JANSSEN	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Apr	NEWA
	43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Apr	NEWA
	70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Apr	NEWA
+	61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010	Apr	NEWA

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORALPANTOPRAZOLE SODIUM

>D> AB	SUN PHARM IND'S	EQ 20MG BASE	A077058 001	Sep 10, 2007	Jun	CAHN
>D> AB		EQ 40MG BASE	A077058 002	Sep 10, 2007	Jun	CAHN
>A> AB	SUN PHARMA GLOBAL	EQ 20MG BASE	A077058 001	Sep 10, 2007	Jun	CAHN
>A> AB		EQ 40MG BASE	A077058 002	Sep 10, 2007	Jun	CAHN

PAROXETINE HYDROCHLORIDETABLET; ORALPAROXETINE HYDROCHLORIDE

>A> AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Jun	NEWA
>A> AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Jun	NEWA
>A> AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Jun	NEWA
>A> AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Jun	NEWA

PEGADEMASE BOVINEINJECTABLE; INJECTIONADAGEN

+ SIGMA TAU	250 UNITS/ML	N019818 001	Mar 21, 1990	Feb	CAHN
-------------	--------------	-------------	--------------	-----	------

PENTETATE CALCIUM TRISODIUMSOLUTION; INHALATION, INTRAVENOUSPENTETATE CALCIUM TRISODIUM

>D>	HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749 001	Aug 11, 2004	Jun	DISC
>A>	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749 001	Aug 11, 2004	Jun	DISC

PENTETATE ZINC TRISODIUMSOLUTION; INHALATION, INTRAVENOUSPENTETATE ZINC TRISODIUM

>D>	HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751 001	Aug 11, 2004	Jun	DISC
>A>	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751 001	Aug 11, 2004	Jun	DISC

PERINDOPRIL ERBUMINETABLET; ORALACEON

AB	ABBOTT PRODS	2MG	N020184 001	Dec 30, 1993	May	CAHN
AB		4MG	N020184 002	Dec 30, 1993	May	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	May	CAHN
	PERINDOPRIL ERBUMINE					
AB	LUPIN LTD	2MG	A078263 001	Jan 27, 2010	Jan	NEWA
AB		4MG	A078263 002	Jan 27, 2010	Jan	NEWA
AB		8MG	A078263 003	Jan 27, 2010	Jan	NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL
BC VALEANT 105MG A088021 001 Sep 21, 1982 Feb CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE
AA BARR 15MG A090591 001 Mar 18, 2010 Mar NEWA
AA 30MG A090591 002 Mar 18, 2010 Mar NEWA

PILOCARPINE HYDROCHLORIDE

>A> SOLUTION; OPHTHALMIC
>A> CARPINE
>A> ALCON 1% N200890 001 Jun 22, 2010 Jun NEWA
>A> 2% N200890 002 Jun 22, 2010 Jun NEWA
>A> + 4% N200890 003 Jun 22, 2010 Jun NEWA

POLIDOCANOL

SOLUTION; INTRAVENOUS
ASCLERA
CHEMISCH FBRK KRSSLR 10MG/2ML (5MG/ML) N021201 001 Mar 30, 2010 Mar NEWA
+ 20MG/2ML (10MG/ML) N021201 002 Mar 30, 2010 Mar NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
LAX-LYTE WITH FLAVOR PACKS
AA PADDOCK 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 A079232 001 Feb 25, 2010 Feb NEWA
1.2GM/BOT
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE
AA MYLAN 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 A090409 001 Apr 02, 2010 Mar NEWA
1.2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL
CLENZ-LYTE
AA PADDOCK LABS 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 A090769 001 Jun 07, 2010 May NEWA
.86GM/BOT;22.74GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL
PEG 3350 AND ELECTROLYTES
AA MYLAN 236GM;2.97GM;6.74GM;5.86GM;22.74G A090928 001 Jan 28, 2010 Jan NEWA
M
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES
AA PADDOCK LABS 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 A090712 001 Feb 25, 2010 Feb NEWA
.84GM/BOT;22.72GM/BOT

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KLOR-CON
BC + UPSHER SMITH 8MEQ N019123 001 Apr 17, 1986 Apr CTEC

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
UROCIT-K
MISSION PHARMA 15MEQ

N019071 003 Dec 30, 2009 Feb NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
AB BOEHRINGER INGELHEIM 0.75MG
PRAMIPEXOLE DIHYDROCHLORIDE
AB MYLAN 0.75MG
>A> AB SANDOZ 0.125MG
>A> AB 0.25MG
>A> AB 0.5MG
>A> AB 1MG
>A> AB 1.5MG
>A> AB ZYDUS PHARMS USA INC 0.125MG
>A> AB 0.25MG
>A> AB 0.5MG
>A> AB 1MG
>A> AB 1.5MG

N020667 007 Jul 30, 2007 Mar CFTG
A090764 001 Apr 09, 2010 Mar NEWA
A090190 001 Jul 06, 2010 Jun NEWA
A090190 002 Jul 06, 2010 Jun NEWA
A090190 003 Jul 06, 2010 Jun NEWA
A090190 004 Jul 06, 2010 Jun NEWA
A090190 005 Jul 06, 2010 Jun NEWA
A078920 001 Jul 06, 2010 Jun NEWA
A078920 002 Jul 06, 2010 Jun NEWA
A078920 003 Jul 06, 2010 Jun NEWA
A078920 004 Jul 06, 2010 Jun NEWA
A078920 005 Jul 06, 2010 Jun NEWA

TABLET, EXTENDED RELEASE; ORAL
MIRAPEX ER
BOEHRINGER INGELHEIM 0.375MG
0.75MG
1.5MG
3MG
+ 4.5MG

N022421 001 Feb 19, 2010 Feb NEWA
N022421 002 Feb 19, 2010 Feb NEWA
N022421 003 Feb 19, 2010 Feb NEWA
N022421 004 Feb 19, 2010 Feb NEWA
N022421 005 Feb 19, 2010 Feb NEWA

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVASTATIN SODIUM
>D> AB COBALT LABS INC 10MG
20MG
40MG
>D> AB 80MG
AB MATRIX LABS LTD 10MG
20MG
40MG
AB 80MG
>A> AB WATSON LABS 10MG
20MG
40MG
>A> AB 80MG

A076939 004 Oct 23, 2006 Jun CAHN
A076939 003 Oct 23, 2006 Jun CAHN
A076939 002 Oct 23, 2006 Jun CAHN
A076939 001 Dec 28, 2007 Jun CAHN
A079187 001 May 27, 2010 May NEWA
A079187 002 May 27, 2010 May NEWA
A079187 003 May 27, 2010 May NEWA
A079187 004 May 27, 2010 May NEWA
A076939 004 Oct 23, 2006 Jun CAHN
A076939 003 Oct 23, 2006 Jun CAHN
A076939 002 Oct 23, 2006 Jun CAHN
A076939 001 Dec 28, 2007 Jun CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HYDROCHLORIDE
@ WATSON LABS EQ 1MG BASE
@ EQ 2MG BASE

A072352 001 May 16, 1989 Jan DISC
A072333 001 May 16, 1989 Jan DISC

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE
@ IVAX SUB TEVA PHARMS 15MG/5ML

A040287 001 May 28, 1999 Apr DISC

PREDNISONE

TABLET; ORAL
PREDNISONE
AB CONTRACT PHARMACAL 5MG A080209 001 Jan CAHN

PREGABALIN

SOLUTION; ORAL
LYRICA
+ PFIZER 20MG/ML N022488 001 Jan 04, 2010 Jan NEWA

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HYDROCHLORIDE
@ WATSON LABS 1% A080658 001 Jan DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE
@ DURAMED PHARMS BARR EQ 5MG BASE A040207 001 May 01, 1997 Jan DISC
@ EQ 10MG BASE A040207 002 May 01, 1997 Jan DISC
PROCOMP
AB CADISTA PHARMS EQ 5MG BASE A040268 001 Feb 27, 1998 Jan CTNA
AB EQ 10MG BASE A040268 002 Feb 27, 1998 Jan CTNA

PROPafenone HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
RYTHMOL SR
>A> GLAXOSMITHKLINE LLC 225MG N021416 001 Sep 04, 2003 Jun CAHN
>A> 325MG N021416 002 Sep 04, 2003 Jun CAHN
>A> + 425MG N021416 003 Sep 04, 2003 Jun CAHN
>D> SMITHKLINE BEECHAM 225MG N021416 001 Sep 04, 2003 Jun CAHN
>D> 325MG N021416 002 Sep 04, 2003 Jun CAHN
>D> + 425MG N021416 003 Sep 04, 2003 Jun CAHN

TABLET; ORAL
RYTHMOL
>A> AB GLAXOSMITHKLINE LLC 150MG N019151 001 Nov 27, 1989 Jun CAHN
>A> AB 225MG N019151 003 Nov 20, 1992 Jun CAHN
>A> AB + 300MG N019151 002 Nov 27, 1989 Jun CAHN
>D> AB SMITHKLINE BEECHAM 150MG N019151 001 Nov 27, 1989 Jun CAHN
>D> AB 225MG N019151 003 Nov 20, 1992 Jun CAHN
>D> AB + 300MG N019151 002 Nov 27, 1989 Jun CAHN

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HYDROCHLORIDE
@ PAR PHARM 65MG A080269 001 Jan DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
INNOPRAN XL
>A> BX GLAXOSMITHKLINE LLC 80MG N021438 001 Mar 12, 2003 Jun CAHN
>A> BX 120MG N021438 002 Mar 12, 2003 Jun CAHN
>D> BX SMITHKLINE BEECHAM 80MG N021438 001 Mar 12, 2003 Jun CAHN
>D> BX 120MG N021438 002 Mar 12, 2003 Jun CAHN

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@	INTERPHARM	10MG	A071368	001	May 05, 1987	May	CAHN	
@		20MG	A071369	001	May 05, 1987	May	CAHN	
@		40MG	A071370	001	May 05, 1987	May	CAHN	
@		80MG	A071371	001	May 05, 1987	May	CAHN	
>A>	AB	PAR PHARM	10MG	A070217	001	Aug 01, 1986	Jun	CMFD
>A>	AB		20MG	A070218	001	Aug 01, 1986	Jun	CMFD
>A>	AB		40MG	A070219	001	Aug 01, 1986	Jun	CMFD
>A>	AB		60MG	A070220	001	Sep 24, 1986	Jun	CMFD
>A>	AB		80MG	A070221	001	Apr 14, 1986	Jun	CMFD
>D>		@ VINTAGE	10MG	A070217	001	Aug 01, 1986	Jun	CMFD
>D>		@	20MG	A070218	001	Aug 01, 1986	Jun	CMFD
>D>		@	40MG	A070219	001	Aug 01, 1986	Jun	CMFD
>D>		@	60MG	A070220	001	Sep 24, 1986	Jun	CMFD
>D>		@	80MG	A070221	001	Apr 14, 1986	Jun	CMFD

PROTRIPTYLINE HYDROCHLORIDETABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	SIGMAPHARM LABS LLC	5MG	A090462	001	May 03, 2010	Apr	NEWA
AB		10MG	A090462	002	May 03, 2010	Apr	NEWA

PYRIMETHAMINETABLET; ORAL

DARAPRIM

>D>	+	GLAXOSMITHKLINE	25MG	N008578	001	Jun	CAHN
>A>	+	GLAXOSMITHKLINE LLC	25MG	N008578	001	Jun	CAHN

QUINIDINE SULFATETABLET; ORAL

QUINIDINE SULFATE

@ CONTRACT PHARMACAL 200MG

A083808 001 Jan CAHN

RAMIPRILCAPSULE; ORAL

RAMIPRIL

>D>	AB	COBALT LABS INC	1.25MG	A076549	001	Oct 24, 2005	Jun	CAHN
>D>	AB		2.5MG	A076549	002	Oct 24, 2005	Jun	CAHN
>D>	AB		5MG	A076549	003	Oct 24, 2005	Jun	CAHN
>D>	AB		10MG	A076549	004	Oct 24, 2005	Jun	CAHN
>A>	AB	WATSON LABS	1.25MG	A076549	001	Oct 24, 2005	Jun	CAHN
>A>	AB		2.5MG	A076549	002	Oct 24, 2005	Jun	CAHN
>A>	AB		5MG	A076549	003	Oct 24, 2005	Jun	CAHN
>A>	AB		10MG	A076549	004	Oct 24, 2005	Jun	CAHN

RANITIDINE HYDROCHLORIDESYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>A>	AA	VINTAGE PHARMS	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010	Jun	NEWA
-----	----	----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	COBALT	EQ 150MG BASE	A077426	001	Dec 19, 2005	Jun	CAHN
>D>	AB		EQ 300MG BASE	A077426	002	Dec 19, 2005	Jun	CAHN
>A>	AB	WATSON LABS	EQ 150MG BASE	A077426	001	Dec 19, 2005	Jun	CAHN
>A>	AB		EQ 300MG BASE	A077426	002	Dec 19, 2005	Jun	CAHN

RIFAXIMIN

TABLET; ORAL
 XIFAXAN
 SALIX PHARMS 550MG N021361 002 Mar 24, 2010 Mar NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR
 RISPERDAL CONSTA
 + ORTHO MCNEIL JANSSEN 25MG/VIAL N021346 001 Oct 29, 2003 Jan CRLD
 50MG/VIAL N021346 003 Oct 29, 2003 Jan CRLD

SOLUTION; ORAL

RISPERIDONE
 >A> AA PRECISION DOSE 1MG/ML A076797 001 Jun 28, 2010 Jun NEWA

TABLET; ORAL
 RISPERIDONE

>D> AB COBALT LABS INC 0.25MG A077860 001 Dec 05, 2008 Jun CAHN

>D> AB 0.5MG A077860 002 Dec 05, 2008 Jun CAHN

>D> AB 1MG A077860 003 Dec 05, 2008 Jun CAHN

>D> AB 2MG A077860 004 Dec 05, 2008 Jun CAHN

>D> AB 3MG A077860 005 Dec 05, 2008 Jun CAHN

>D> AB 4MG A077860 006 Dec 05, 2008 Jun CAHN

AB RATIOPHARM 0.25MG A077784 001 Jun 08, 2010 May NEWA

AB 0.5MG A077784 002 Jun 08, 2010 May NEWA

AB 1MG A077784 003 Jun 08, 2010 May NEWA

AB 2MG A077784 004 Jun 08, 2010 May NEWA

AB 3MG A077784 005 Jun 08, 2010 May NEWA

AB 4MG A077784 006 Jun 08, 2010 May NEWA

@ SYNTHON PHARMS 0.25MG A078187 001 Oct 22, 2009 Feb DISC

@ 0.5MG A078187 002 Oct 22, 2009 Feb DISC

@ 1MG A078187 003 Oct 22, 2009 Feb DISC

@ 2MG A078187 004 Oct 22, 2009 Feb DISC

@ 3MG A078187 005 Oct 22, 2009 Feb DISC

@ 4MG A078187 006 Oct 22, 2009 Feb DISC

>A> AB WATSON LABS 0.25MG A077860 001 Dec 05, 2008 Jun CAHN

>A> AB 0.5MG A077860 002 Dec 05, 2008 Jun CAHN

>A> AB 1MG A077860 003 Dec 05, 2008 Jun CAHN

>A> AB 2MG A077860 004 Dec 05, 2008 Jun CAHN

>A> AB 3MG A077860 005 Dec 05, 2008 Jun CAHN

>A> AB 4MG A077860 006 Dec 05, 2008 Jun CAHN

RITONAVIR

TABLET; ORAL
 NORVIR
 + ABBOTT LABS 100MG N022417 001 Feb 10, 2010 May CTNA
 RITONAVIR
 + ABBOTT LABS 100MG N022417 001 Feb 10, 2010 Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
 EXELON
 AB NOVARTIS EQ 6MG BASE N020823 006 Apr 21, 2000 Feb CRLD

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	BIONICHE PHARMA USA	50MG/5ML (10MG/ML)	A079199 001	Nov 26, 2008	Mar	CAHN
AP		100MG/10ML (10MG/ML)	A079199 002	Nov 26, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC LTD	EQ 0.25MG BASE	A090429 001	Mar 24, 2010	Mar	NEWA
AB		EQ 0.5MG BASE	A090429 002	Mar 24, 2010	Mar	NEWA
AB		EQ 1MG BASE	A090429 003	Mar 24, 2010	Mar	NEWA
AB		EQ 2MG BASE	A090429 004	Mar 24, 2010	Mar	NEWA
AB		EQ 3MG BASE	A090429 005	Mar 24, 2010	Mar	NEWA
AB		EQ 4MG BASE	A090429 006	Mar 24, 2010	Mar	NEWA
AB		EQ 5MG BASE	A090429 007	Mar 24, 2010	Mar	NEWA
AB	GLENMARK GENERICS	EQ 0.25MG BASE	A090135 001	Feb 25, 2010	Feb	NEWA
AB		EQ 0.5MG BASE	A090135 002	Feb 25, 2010	Feb	NEWA
AB		EQ 1MG BASE	A090135 003	Feb 25, 2010	Feb	NEWA
AB		EQ 2MG BASE	A090135 004	Feb 25, 2010	Feb	NEWA
AB		EQ 3MG BASE	A090135 005	Feb 25, 2010	Feb	NEWA
AB		EQ 4MG BASE	A090135 006	Feb 25, 2010	Feb	NEWA
AB		EQ 5MG BASE	A090135 007	Feb 25, 2010	Feb	NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	MYLAN	5MG	A074866 001	Nov 26, 1997	Mar	CAHN
----	-------	-----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	COBALT	EQ 25MG BASE	A077663 001	Feb 06, 2007	Jun	CAHN
>D>	AB		EQ 50MG BASE	A077663 002	Feb 06, 2007	Jun	CAHN
>D>	AB		EQ 100MG BASE	A077663 003	Feb 06, 2007	Jun	CAHN
		@ SANDOZ	EQ 25MG BASE	A077713 001	Feb 06, 2007	May	DISC
		@	EQ 50MG BASE	A077713 002	Feb 06, 2007	May	DISC
		@	EQ 100MG BASE	A077713 003	Feb 06, 2007	May	DISC
>A>	AB	WATSON LABS	EQ 25MG BASE	A077663 001	Feb 06, 2007	Jun	CAHN
>A>	AB		EQ 50MG BASE	A077663 002	Feb 06, 2007	Jun	CAHN
>A>	AB		EQ 100MG BASE	A077663 003	Feb 06, 2007	Jun	CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>D>	AB	COBALT	5MG	A076685 001	Dec 20, 2006	Jun	CAHN
>D>	AB		10MG	A076685 002	Dec 20, 2006	Jun	CAHN
>D>	AB		20MG	A076685 003	Dec 20, 2006	Jun	CAHN
>D>	AB		40MG	A076685 004	Dec 20, 2006	Jun	CAHN
>D>	AB		80MG	A076685 005	Dec 20, 2006	Jun	CAHN
	AB	MATRIX LABS LTD	5MG	A090868 001	Jun 08, 2010	May	NEWA
	AB		10MG	A090868 002	Jun 08, 2010	May	NEWA
	AB		20MG	A090868 003	Jun 08, 2010	May	NEWA
	AB		40MG	A090868 004	Jun 08, 2010	May	NEWA
	AB		80MG	A090868 005	Jun 08, 2010	May	NEWA

TABLET; ORALSIMVASTATIN

>A>	AB	WATSON LABS	5MG	A076685	001	Dec 20,	2006	Jun	CAHN
>A>	AB		10MG	A076685	002	Dec 20,	2006	Jun	CAHN
>A>	AB		20MG	A076685	003	Dec 20,	2006	Jun	CAHN
>A>	AB		40MG	A076685	004	Dec 20,	2006	Jun	CAHN
>A>	AB		80MG	A076685	005	Dec 20,	2006	Jun	CAHN

SIROLIMUSTABLET; ORALRAPAMUNE

>A>		WYETH PHARMS INC	0.5MG	N021110	004	Jan 25,	2010	Jun	NEWA
-----	--	------------------	-------	---------	-----	---------	------	-----	------

SODIUM BICARBONATEINJECTABLE; INJECTIONSODIUM BICARBONATE

+	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09,	2005	Feb	CRLD
---	---------	-----------	---------	-----	---------	------	-----	------

SOMATROPIN RECOMBINANTINJECTABLE; INJECTIONNORDITROPIN FLEXPRO

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01,	2010	Mar	NEWA
BX			10MG/1.5ML	N021148	009	Mar 01,	2010	Mar	NEWA
BX			15MG/1.5ML	N021148	010	Mar 01,	2010	Mar	NEWA

SPIRONOLACTONETABLET; ORALSPIRONOLACTONE

>A>	AB	AMNEAL PHARMS	25MG	A091426	001	Jun 08,	2010	Jun	NEWA
>A>	AB		50MG	A091426	002	Jun 08,	2010	Jun	NEWA
>A>	AB		100MG	A091426	003	Jun 08,	2010	Jun	NEWA

STAVUDINECAPSULE; ORALSTAVUDINE

AB		MYLAN	15MG	A079069	001	Dec 29,	2008	Feb	CAHN
AB			20MG	A079069	002	Dec 29,	2008	Feb	CAHN
AB			30MG	A079069	003	Dec 29,	2008	Feb	CAHN
AB			40MG	A079069	004	Dec 29,	2008	Feb	CAHN

SUCRALFATETABLET; ORALSUCRALFATE

AB		NOSTRUM LABS	1GM	A074415	001	Jun 08,	1998	Mar	CAHN
----	--	--------------	-----	---------	-----	---------	------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIMSUSPENSION; ORALSULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AUROBINDO PHARMA	200MG/5ML;40MG/5ML	A091348	001	Jun 08,	2010	May	NEWA
AB	+	HI TECH PHARMA	200MG/5ML;40MG/5ML	A074650	001	Dec 29,	1997	May	CRLD
	@	TEVA PHARMS	200MG/5ML;40MG/5ML	A077612	001	Nov 13,	2006	May	DISC

TABLET; ORALSULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AUROBINDO PHARMA	400MG;80MG	A090624	001	Feb 16,	2010	Jan	NEWA
AB			800MG;160MG	A090624	002	Feb 16,	2010	Jan	NEWA
	@	INTERPHARM	400MG;80MG	A071299	001	Oct 27,	1987	May	CAHN

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM
 @ INTERPHARM 800MG;160MG

A071300 001 Oct 27, 1987 May CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE
 @ IVAX SUB TEVA PHARMS 500MG

A080142 001 Apr DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

>A>	ALSUMA					
>A>	+ KING PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Jun NEWA
AP	SUMATRIPTAN SUCCINATE SAGENT STRIDES	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	May NEWA
>D>	SUMAVEL DOSEPRO + ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N022239	001	Jul 15, 2009	Jun CPOT
>A>	+ SUMATRIPTAN SUCCINATE COBALT LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	Jun CPOT
>D> AB	TABLET; ORAL WATSON LABS	EQ 25MG BASE	A076933	001	Aug 10, 2009	Jun CAHN
>D> AB		EQ 50MG BASE	A076933	002	Aug 10, 2009	Jun CAHN
>D> AB		EQ 100MG BASE	A076933	003	Aug 10, 2009	Jun CAHN
>A> AB		EQ 25MG BASE	A076933	001	Aug 10, 2009	Jun CAHN
>A> AB		EQ 50MG BASE	A076933	002	Aug 10, 2009	Jun CAHN
>A> AB		EQ 100MG BASE	A076933	003	Aug 10, 2009	Jun CAHN

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB	DR REDDYS LABS LTD	EQ 0.5MG BASE	A090509	001	May 12, 2010	May NEWA
AB		EQ 1MG BASE	A090509	002	May 12, 2010	May NEWA
AB		EQ 5MG BASE	A090509	003	May 12, 2010	May NEWA
>A> AB	WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010	Jun NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

AB	+ BOEHRINGER INGELHEIM	0.4MG	N020579	001	Apr 15, 1997	Feb CFTG
AB	IMPAX LABS	0.4MG	A090377	001	Mar 02, 2010	Feb NEWA
AB	MYLAN	0.4MG	A090408	001	Apr 27, 2010	Apr NEWA
AB	SANDOZ	0.4MG	A078015	001	Apr 27, 2010	Apr NEWA
AB	SYNTON PHARMS	0.4MG	A078801	001	Apr 27, 2010	Apr NEWA
AB	TEVA PHARMS	0.4MG	A077630	001	Apr 27, 2010	Apr NEWA
AB	WOCKHARDT	0.4MG	A078938	001	Apr 27, 2010	Apr NEWA
AB	ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Apr NEWA

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE

+ LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001	Feb	CRLD
------------------	-------------------------	---------	-----	-----	------

SOLUTION; INJECTION, ORAL

ULTRA-TECHNEKOW FM

+ MALLINCKRODT 0.25-3 CI/GENERATOR

N017243 002

Feb CRLD

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB MYLAN 7.5MG A070920 002 May 21, 2010 May NEWA

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB SCHERING	5MG	N021029 001 Aug 11, 1999 Feb CFTG
AB	20MG	N021029 002 Aug 11, 1999 Feb CFTG
AB	100MG	N021029 003 Aug 11, 1999 Feb CFTG
AB	140MG	N021029 005 Oct 19, 2006 Feb CFTG
AB	180MG	N021029 006 Oct 19, 2006 Feb CFTG
AB +	250MG	N021029 004 Aug 11, 1999 Feb CFTG
TEMOZOLOMIDE		
AB BARR	5MG	A078879 001 Mar 01, 2010 Feb NEWA
AB	20MG	A078879 002 Mar 01, 2010 Feb NEWA
AB	100MG	A078879 003 Mar 01, 2010 Feb NEWA
AB	140MG	A078879 005 Mar 01, 2010 Feb NEWA
AB	180MG	A078879 006 Mar 01, 2010 Feb NEWA
AB	250MG	A078879 004 Mar 01, 2010 Feb NEWA

TERBINAFINE

>D>	GEL; TOPICAL		
>D>	LAMISIL		
>D>	NOVARTIS	1%	N020846 001 Apr 29, 1998 Jun DISC
>A>	@	1%	N020846 001 Apr 29, 1998 Jun DISC

TERBINAFINE HYDROCHLORIDE

>D>	SOLUTION; TOPICAL		
>D>	LAMISIL		
>D>	+ NOVARTIS	1%	N020749 001 Oct 17, 1997 Jun DISC
>A>	@	1%	N020749 001 Oct 17, 1997 Jun DISC
TABLET; ORAL			
TERBINAFINE HYDROCHLORIDE			
AB BRECKENRIDGE PHARM	EQ 250MG BASE	A077714 001 Jun 04, 2010 May NEWA	
>D> AB GEDEON RICHTER USA	EQ 250MG BASE	A077065 001 Jul 02, 2007 Jun DISC	
>A> @	EQ 250MG BASE	A077065 001 Jul 02, 2007 Jun DISC	

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

BX + NYCOMED US 0.8% N021735 001 Oct 01, 2004 Jan CAHN

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

>D>	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318 002 Jun 25, 2008 Jun CRLD
>A>	+	0.6MG/2.4ML (0.25MG/ML)	N021318 002 Jun 25, 2008 Jun CRLD
>D>	+	0.75MG/3ML (0.25MG/ML)	N021318 001 Nov 26, 2002 Jun DISC
>A>	@	0.75MG/3ML (0.25MG/ML)	N021318 001 Nov 26, 2002 Jun DISC

THEOPHYLLINE

ELIXIR; ORAL						
ELIXOPHYLLIN						
+ CARACO	80MG/15ML		A085186 001		Mar	CAHN
TABLET, EXTENDED RELEASE; ORAL						
THEOCHRON						
AB CARACO	100MG		A088320 001	Feb 21, 1985	Mar	CAHN
AB	200MG		A088321 001	Feb 21, 1985	Mar	CAHN
AB	300MG		A087400 002	Jan 11, 1983	Mar	CAHN
THEOPHYLLINE						
>A> AB GLENMARK GENERICS	400MG		A090355 001	Jul 13, 2010	Jun	NEWA
>A> AB	600MG		A090355 002	Jul 13, 2010	Jun	NEWA
>D> AB NOSTRUM	400MG		A040595 001	Apr 21, 2006	Jun	CTEC
>A>	400MG		A040595 001	Apr 21, 2006	Jun	CTEC
>D> AB	600MG		A040560 002	Apr 21, 2006	Jun	CRLD
>A> +	600MG		A040560 002	Apr 21, 2006	Jun	CRLD
>D> UNIPHYL						
>D> AB PURDUE PHARM PRODS	400MG		A087571 001	Sep 01, 1982	Jun	DISC
>A> @	400MG		A087571 001	Sep 01, 1982	Jun	DISC
>D> AB +	600MG		A040086 001	Apr 15, 1996	Jun	DISC
>A> @	600MG		A040086 001	Apr 15, 1996	Jun	DISC

TINZAPARIN SODIUM

INJECTABLE; INJECTION						
INNOHEP						
+ LEO PHARMA AS	20,000 IU/ML		N020484 001	Jul 14, 2000	Feb	CAHN

TOLAZAMIDE

TABLET; ORAL						
TOLAZAMIDE						
@ INTERPHARM	250MG		A071270 001	Sep 23, 1986	May	CAHN
@	500MG		A071271 001	Sep 23, 1986	May	CAHN

TOLMETIN SODIUM

TABLET; ORAL						
TOLMETIN SODIUM						
@ IVAX SUB TEVA PHARMS	EQ 600MG BASE		A074399 001	Mar 28, 1996	Apr	DISC

TOPIRAMATE

CAPSULE; ORAL						
TOPIRAMATE						
>D> AB COBALT LABS INC	15MG		A077868 001	Apr 15, 2009	Jun	CAHN
>D> AB	25MG		A077868 002	Apr 15, 2009	Jun	CAHN
>A> AB WATSON LABS	15MG		A077868 001	Apr 15, 2009	Jun	CAHN
>A> AB	25MG		A077868 002	Apr 15, 2009	Jun	CAHN
TABLET; ORAL						
TOPIRAMATE						
>D> AB COBALT LABS INC	25MG		A077643 001	Mar 27, 2009	Jun	CAHN
>D> AB	50MG		A077643 002	Mar 27, 2009	Jun	CAHN
>D> AB	100MG		A077643 003	Mar 27, 2009	Jun	CAHN
>D> AB	200MG		A077643 004	Mar 27, 2009	Jun	CAHN
@ PLIVA HRVATSKA DOO	25MG		A077905 001	Mar 30, 2009	Jan	DISC
@	50MG		A077905 002	Mar 30, 2009	Jan	DISC
@	100MG		A077905 003	Mar 30, 2009	Jan	DISC
@	200MG		A077905 004	Mar 30, 2009	Jan	DISC

TABLET; ORAL

TOPIRAMATE

>A>	AB	WATSON LABS	25MG	A077643	001	Mar 27, 2009	Jun	CAHN
>A>	AB		50MG	A077643	002	Mar 27, 2009	Jun	CAHN
>A>	AB		100MG	A077643	003	Mar 27, 2009	Jun	CAHN
>A>	AB		200MG	A077643	004	Mar 27, 2009	Jun	CAHN

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

	AP	+	BEDFORD LABS	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Apr	CTECC
	AP	+		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Apr	CTECC
>A>	AP		LUITPOLD	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jun	CAHN
>A>	AP			20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jun	CAHN
>D>	AP		PHARMAFORCE	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jun	CAHN
>D>	AP			50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jun	CAHN
	AP			50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Apr	NEWA
	AP			20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Apr	NEWA

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

+ CIPHER PHARMS INC 100MG N022370 001 May 07, 2010 May NEWA
200MG N022370 002 May 07, 2010 May NEWA
300MG N022370 003 May 07, 2010 May NEWA

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB NORTHSTAR HLTHCARE 50MG A078935 001 May 26, 2010 May NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

+ VICTORY PHARMA 50MG N021693 001 May 05, 2005 Mar CMFD

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

>D>	AB	COBALT	1MG	A077805	001	Jun 12, 2007	Jun	CAHN
>D>	AB		2MG	A077805	002	Jun 12, 2007	Jun	CAHN
>D>	AB		4MG	A077805	003	Jun 12, 2007	Jun	CAHN
	AB	EPIC PHARMA	1MG	A078508	003	Jun 18, 2008	Feb	CAHN
	AB		2MG	A078508	001	Jun 18, 2008	Feb	CAHN
	AB		4MG	A078508	002	Jun 18, 2008	Feb	CAHN
>A>	AB	WATSON LABS	1MG	A077805	001	Jun 12, 2007	Jun	CAHN
>A>	AB		2MG	A077805	002	Jun 12, 2007	Jun	CAHN
>A>	AB		4MG	A077805	003	Jun 12, 2007	Jun	CAHN

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

AB	ABBOTT	2MG;180MG	N020591 001	Oct 22, 1996	May	CFTG
AB		2MG;240MG	N020591 004	Oct 22, 1996	May	CFTG
AB	+	4MG;240MG	N020591 002	Oct 22, 1996	Apr	CFTG

TRANDOLARBITAL AND VERARAMBUTYL HYDROCHLORIDE

AB	GLENMARK GENERICS	2MG;180MG	A079135 001	May 26, 2010	May	NEWA
AB		2MG;240MG	A079135 002	May 26, 2010	May	NEWA
AB		4MG;240MG	A079135 003	May 05, 2010	Apr	NEWA

TRANEXAMIC ACID

TABLET; ORAL
 LYSTEDA
 + FERRING PHARMS AS 650MG N022430 001 Nov 13, 2009 May CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
 TRAZODONE HYDROCHLORIDE
 AB VINTAGE 50MG A072192 001 Feb 02, 1989 Feb CAHN
 AB 100MG A072193 001 Feb 02, 1989 Feb CAHN
 TABLET, EXTENDED RELEASE; ORAL
 OLEPTRO
 LABOPHARM 150MG N022411 001 Feb 02, 2010 Feb NEWA
 + 300MG N022411 002 Feb 02, 2010 Feb NEWA

TRETINOIN

CAPSULE; ORAL
 TRETINOIN
 + BARR 10MG A077684 001 Jun 22, 2007 Feb CRLD
 VESANOID
 @ ROCHE 10MG N020438 001 Nov 22, 1995 Feb DISC
 CREAM; TOPICAL
 TRETINOIN
 + TRIAX PHARMS LLC 0.0375% A090098 001 Mar 22, 2010 Mar NEWA

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL
 ORACORT
 >D> + TARO 0.1% A070730 001 Oct 01, 1986 Jun CFTG
 >A> AT + 0.1% A070730 001 Oct 01, 1986 Jun CFTG
 >A> TRIAMCINOLONE ACETONIDE
 >A> AT LYNE 0.1% A040771 001 Jul 01, 2010 Jun NEWA

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR
 TRELSTAR
 + WATSON LABS EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010 Mar NEWA

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
 RESCULA
 @ SUCAMPO PHARMS 0.15% N021214 001 Aug 03, 2000 Jan DISC

UREA, C-14

CAPSULE; ORAL
 PYTEST
 + AVENT 1uCi N020617 001 May 09, 1997 Feb CAHN
 PYTEST KIT
 + AVENT 1uCi N020617 002 May 09, 1997 Feb CAHN

URSODIOL

CAPSULE; ORAL
 URSODIOL
 AB EPIC PHARMA 300MG A075517 001 Mar 14, 2000 May CAHN
 AB MIKAH PHARMA 300MG A075517 001 Mar 14, 2000 Feb CAHN

CAPSULE; ORAL

URSDIOL

AB MYLAN 300MG A090530 001 Feb 17, 2010 Jan NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	AUROBINDO PHARMA	EQ 500MG BASE	A090682 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A090682 002 May 24, 2010 May NEWA
AB	DR REDDYS LABS LTD	EQ 500MG BASE	A079012 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A079012 002 May 24, 2010 May NEWA
AB	MATRIX LABS LTD	EQ 500MG BASE	A078518 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A078518 002 May 24, 2010 May NEWA
AB	MYLAN	EQ 500MG BASE	A078070 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A078070 002 May 24, 2010 May NEWA
AB	ROXANE	EQ 500MG BASE	A078656 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A078656 002 May 24, 2010 May NEWA
AB	SANDOZ	EQ 500MG BASE	A077478 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A077478 002 May 24, 2010 May NEWA
AB	TEVA PHARMS	EQ 500MG BASE	A077655 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A077655 002 May 24, 2010 May NEWA
AB	WATSON LABS	EQ 500MG BASE	A077135 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A077135 002 May 24, 2010 May NEWA
AB	WOCKHARDT	EQ 500MG BASE	A090216 001 May 24, 2010 May NEWA
AB		EQ 1GM BASE	A090216 002 May 24, 2010 May NEWA

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

AP HIKMA FARMACEUTICA EQ 100MG BASE/ML A078523 001 Feb 17, 2010 Jan NEWA

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

@ APOTEX INC

AA SUN PHARM IND'S INC 250MG/5ML A077105 001 Jul 29, 2005 May DISC

A090517 001 May 28, 2010 May NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	BIONICHE PHARMA USA	EQ 500MG BASE/VIAL	A065401 001 Jun 30, 2008 Mar CAHN
AP		EQ 1GM BASE/VIAL	A065401 002 Jun 30, 2008 Mar CAHN
AP	SANDOZ	EQ 500MG BASE/VIAL	A090250 001 Apr 27, 2010 Apr NEWA
AP		EQ 1GM BASE/VIAL	A090250 002 Apr 27, 2010 Apr NEWA

VARDENAFIL HYDROCHLORIDE

>A> TABLET, ORALLY DISINTEGRATING; ORAL

>A> STAXYN

>A> + BAYER HLTHCARE 10MG N200179 001 Jun 17, 2010 Jun NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	AKORN STRIDES	10MG/VIAL	A090243 001 May 11, 2010 May NEWA
AP		20MG/VIAL	A090243 002 May 11, 2010 May NEWA
AP	MUSTAFA NEVZAT	10MG/VIAL	A078274 001 Dec 29, 2008 Mar CAHN

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP MUSTAFA NEVZAT 20MG/VIAL

A078274 002 Dec 29, 2008 Mar CAHN

VELAGLUCERASE ALFAINJECTABLE; IV (INFUSION)

VPRI

SHIRE HUMAN GENETIC 400 UNITS/VIAL

N022575 001 Feb 26, 2010 Feb NEWA

POWDER; IV (INFUSION)

VPRI

+ SHIRE HUMAN GENETIC 200 UNITS/VIAL

N022575 002 Feb 26, 2010 Feb NEWA

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

>D> WYETH PHARMS INC EQ 37.5MG BASE

N020699 001 Oct 20, 1997 Jun CFTG

>A> AB EQ 37.5MG BASE

N020699 001 Oct 20, 1997 Jun CFTG

>D> EQ 75MG BASE

N020699 002 Oct 20, 1997 Jun CFTG

>A> AB EQ 75MG BASE

N020699 002 Oct 20, 1997 Jun CFTG

>D> + EQ 150MG BASE

N020699 004 Oct 20, 1997 Jun CFTG

>A> AB + EQ 150MG BASE

N020699 004 Oct 20, 1997 Jun CFTG

>A> VENLAFAXINE HYDROCHLORIDE

>A> AB TEVA EQ 37.5MG BASE

A076565 001 Jun 28, 2010 Jun NEWA

>A> AB EQ 75MG BASE

A076565 002 Jun 28, 2010 Jun NEWA

>A> AB EQ 150MG BASE

A076565 003 Jun 28, 2010 Jun NEWA

TABLET; ORALVENLAFAXINE HYDROCHLORIDE

>A> AB AMNEAL PHARMS EQ 25MG BASE

A079098 001 May 11, 2010 Jun CAHN

>A> AB EQ 37.5MG BASE

A079098 002 May 11, 2010 Jun CAHN

>A> AB EQ 50MG BASE

A079098 003 May 11, 2010 Jun CAHN

>A> AB EQ 75MG BASE

A079098 004 May 11, 2010 Jun CAHN

>A> AB EQ 100MG BASE

A079098 005 May 11, 2010 Jun CAHN

AB AUROBINDO PHARMA EQ 25MG BASE

A090555 001 Apr 07, 2010 Mar NEWA

AB EQ 37.5MG BASE

A090555 002 Apr 07, 2010 Mar NEWA

AB EQ 50MG BASE

A090555 003 Apr 07, 2010 Mar NEWA

AB EQ 75MG BASE

A090555 004 Apr 07, 2010 Mar NEWA

AB EQ 100MG BASE

A090555 005 Apr 07, 2010 Mar NEWA

>D> AB INTERPHARM EQ 25MG BASE

A079098 001 May 11, 2010 Jun CAHN

AB EQ 25MG BASE

A079098 001 May 11, 2010 Apr NEWA

>D> AB EQ 37.5MG BASE

A079098 002 May 11, 2010 Jun CAHN

AB EQ 37.5MG BASE

A079098 002 May 11, 2010 Apr NEWA

>D> AB EQ 50MG BASE

A079098 003 May 11, 2010 Jun CAHN

AB EQ 50MG BASE

A079098 003 May 11, 2010 Apr NEWA

>D> AB EQ 75MG BASE

A079098 004 May 11, 2010 Jun CAHN

AB EQ 75MG BASE

A079098 004 May 11, 2010 Apr NEWA

>D> AB EQ 100MG BASE

A079098 005 May 11, 2010 Jun CAHN

AB EQ 100MG BASE

A079098 005 May 11, 2010 Apr NEWA

VORICONAZOLETABLET; ORAL

VFEND

AB PFIZER 50MG

N021266 001 May 24, 2002 Apr CFTG

AB + 200MG

N021266 002 May 24, 2002 Apr CFTG

VORICONAZOLE

AB MATRIX LABS LTD 50MG

A090547 001 Apr 22, 2010 Apr NEWA

AB 200MG

A090547 002 Apr 22, 2010 Apr NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL
PRIALT

+ AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060 002 Dec 28, 2004 May CAHN
@	200MCG/2ML (100MCG/ML)	N021060 003 Dec 28, 2004 May CAHN
+	500MCG/5ML (100MCG/ML)	N021060 004 Dec 28, 2004 May CAHN
+	500MCG/20ML (25MCG/ML)	N021060 001 Dec 28, 2004 May CAHN

ZIDOVUDINE

INJECTABLE; INJECTION
RETROVIR

AP + VIIV HLTHCARE	10MG/ML	N019951 001 Feb 02, 1990 Apr CFTG
ZIDOVUDINE		
AP PHARMAFORCE	10MG/ML	A091457 001 May 06, 2010 Apr NEWA

ZILEUTON

TABLET; ORAL
ZYFLO

@ CORNERSTONE THERAP	300MG	N020471 001 Dec 09, 1996 May CAHN
+	600MG	N020471 003 Dec 09, 1996 May CAHN

TABLET, EXTENDED RELEASE; ORAL
ZYFLO CR

+ CORNERSTONE THERAP	600MG	N022052 001 May 30, 2007 May CAHN
----------------------	-------	-----------------------------------

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

@ WORLD GEN	5MG	A076062 001 Apr 23, 2007 Mar CAHN
@	10MG	A076062 002 Apr 23, 2007 Mar CAHN

OTC DRUG PRODUCT LIST - 30TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

PERRIGO NEW YORK

120MG

A070607 001 Apr 06, 1987 May CAHN

650MG

A070608 001 Dec 01, 1986 May CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA 5MG/5ML

A090750 002 Feb 02, 2010 Jan NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA 5MG/5ML

A090750 001 Feb 02, 2010 Jan NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG

A078780 001 Jan 21, 2010 Jan NEWA

10MG

A078780 004 Jan 21, 2010 Jan NEWA

CADISTA PHARMS 5MG

A078933 001 Jun 15, 2010 May NEWA

10MG

A078933 002 Jun 15, 2010 May NEWA

TORRENT PHARMS LLC 5MG

A079191 001 Apr 15, 2010 Mar NEWA

10MG

A079191 004 Apr 15, 2010 Mar NEWA

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS 5MG

A078933 003 Jun 15, 2010 May NEWA

10MG

A078933 004 Jun 15, 2010 May NEWA

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY 5MG

A078780 003 Jan 21, 2010 Jan NEWA

10MG

A078780 002 Jan 21, 2010 Jan NEWA

TORRENT PHARMS LLC 5MG

A079191 003 Apr 15, 2010 Mar NEWA

10MG

A079191 002 Apr 15, 2010 Mar NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

CONTRACT PHARMACAL 200MG

A074961 001 Jun 19, 1998 Jan CAHN

200MG

A074963 001 Jun 19, 1998 Jan CAHN

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO 10MG

A075715 001 Aug 22, 2003 Apr CRLD

PEPCID AC

+ MERCK 20MG

N020801 002 Dec 17, 2007 Apr CRLD

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

+ CONTRACT PHARMACAL 200MG

A074782 001 Jul 06, 1998 Jan CAHN

TABLET; ORAL

IBUPROFEN

CONTRACT PHARMACAL 200MG

A071732 001 Sep 10, 1987 Jan CAHN

200MG

A071735 001 Sep 10, 1987 Jan CAHN

200MG

A072299 001 Jul 01, 1988 Jan CAHN

200MG

A073691 001 Feb 25, 1994 Jan CAHN

TABLET; ORAL

PROFEN

CONTRACT PHARMACAL 200MG

A071265 001 Oct 15, 1986 Jan CAHN

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

+ WYETH CONS 200MG;10MG

N022565 001 May 27, 2010 May NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL 200MG;30MG

A075588 001 Apr 08, 2002 Jan CAHN

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

+ WATSON LABS 0.75MG

A078665 001 Aug 28, 2009 Apr CRLD

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

CONTRACT PHARMACAL 2MG

A073254 001 Jul 30, 1993 Jan CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH 5MG;120MG

N019670 002 Nov 27, 2002 Mar CMFD

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS 5MG;120MG

A076050 001 Jan 30, 2003 Mar CRLD

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 4%

A091366 001 Jan 15, 2010 Jan NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>A AVACOR PRODS 5%

A075619 001 Nov 17, 2000 Jun CMFD

>D @ TEVA 5%

A075619 001 Nov 17, 2000 Jun CMFD

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

VISINE-A

+ JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996 Jan CRLD

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

+ AZTIQ PHARMA 1GM

N018683 001 Apr 01, 1983 May CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

SUDAFED 24 HOUR

+ MCNEIL CONS 240MG

N020021 002 Dec 15, 1992 Feb CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

CONTRACT PHARMACAL EQ 75MG BASE

A075094 001 Jun 21, 1999 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2010

NO JUNE 2010 APPROVALS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	>A> 7737181	Aug 29, 2024	DP			
<u>ADAPALENE - DIFFERIN</u>						
N022502 001					NDF	Mar 17, 2013
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N021575 001	5994329	Jul 17, 2018		Y		
	6015801	Jul 17, 2018		Y		
	6225294	Jul 17, 2018		Y		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002					NCE	Mar 05, 2012
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	7723910	Jun 17, 2019	U-289		M-82	Mar 12, 2013
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 001	7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 002	7709444	Apr 12, 2021	DP U-540			
<u>APREPITANT - EMEND</u>						
N021549 001					M-82	Mar 19, 2013
<u>APREPITANT - EMEND</u>						
N021549 002	5719147	Apr 17, 2015	DS DP U-853		M-82	Mar 19, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N021549 003	5719147	Apr 17, 2015	DS DP U-853		M-82	Mar 19, 2013
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N021881 001	7658914	Sep 01, 2024	DS DP			
<u>AZTREONAM - CAYSTON</u>						
N050814 001	7208141	Dec 20, 2021	DP U-1031			
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N020610 001	7452872	Aug 24, 2026	U-141			
	7452872*PED	Feb 24, 2027				
	7625884	Aug 24, 2026	U-141			
	7625884*PED	Feb 24, 2027				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	6780877	Dec 25, 2017	DS DP			
<u>BEXAROTENE - TARGRETIN</u>						
N021055 001	7655699	Apr 22, 2012	DS DP U-509			
<u>BEXAROTENE - TARGRETIN</u>						
N021056 001	7655699	Apr 22, 2012	DS DP U-510			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	May 23, 2010	DS DP U-1040			
	5196404*PED	Nov 23, 2010				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 001	6686346	Apr 29, 2017	DP U-557	Y		
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699	Y		
	6986904*PED	Oct 29, 2017				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 002	6686346	Apr 29, 2017	DP U-557			
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699			
	6986904*PED	Oct 29, 2017				
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 001	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 002	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 003	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>CAPSAICIN - QUTENZA</u>						
N022395 001					ODE	Nov 16, 2016
<u>CARGLUMIC ACID - CARBAGLU</u>						
N022562 001					NCE	Mar 18, 2015
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 001	5599557	Feb 04, 2014	DP U-578			
	5599557	Feb 04, 2014	DP U-282			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 002	5599557	Feb 04, 2014	DP U-578			
	5599557	Feb 04, 2014	DP U-282			
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	>A> 6264923	May 13, 2018	DP			
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	>A> 6264923	May 13, 2018	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 001	7709022	Jun 23, 2021	DP			
	7709022*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 002	7709022	Jun 23, 2021	DP			
	7709022*PED	Dec 23, 2021				
<u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u>						
A090785 001					PC	Sep 27, 2010
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N050802 001	RE41134	Feb 24, 2015	DP U-1033			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021644 001	7700081	Jan 03, 2022	U-1044			
<u>CLOFARABINE - CLOLAR</u>						
N021673 001	5661136	Jan 14, 2018	U-626			
	5661136*PED	Jul 14, 2018				
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331 001	5869100	Oct 13, 2013	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 001	5607669	Jun 10, 2014		U-757		
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014		U-757		
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-757		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-757		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-493		
	7229613*PED	Oct 17, 2022				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 002	5607669	Jun 10, 2014		U-757		
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014		U-757		
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-757		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-757		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-493		
	7229613*PED	Oct 17, 2022				
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	5370879	Dec 06, 2011	DP		NCE	Jan 22, 2015
	5540938	Jul 30, 2013	U-1030		ODE	Jan 22, 2017
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	6037157	Jun 26, 2016		U-935		
	6703403	Jun 26, 2016		U-935		
	7470506	Jun 23, 2019		U-935		
	7700645	Dec 26, 2026	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	6037157	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-935			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	6037157	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-935			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	6037157	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-935			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	6037157	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-935			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
<u>DECITABINE - DACOGEN</u>						
N021790 001					D-123	Mar 11, 2013
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	7482377	May 15, 2017	DS DP U-436		NDF	Jun 17, 2012
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	>A> 6133251	Oct 25, 2016	DP U-828		NP	May 06, 2013
	>A> 6133251	Oct 25, 2016	DP U-112			
	>A> 6133251	Oct 25, 2016	DP U-1			
	>A> 6884793	Oct 25, 2016	DP			
<u>DOCETAXEL - TAXOTERE</u>						
N020449 001	4814470	May 14, 2010	DS DP		I-543	Sep 28, 2010
	4814470*PED	Nov 14, 2010			I-542	Sep 28, 2010
	5438072	Nov 22, 2013	DP		M-61	May 13, 2013
	5438072*PED	May 22, 2014			PED	Nov 13, 2013
	5698582	Jul 03, 2012	DP		PED	Mar 28, 2011
	5698582*PED	Jan 03, 2013				
	5714512	Jul 03, 2012	DP			
	5714512*PED	Jan 03, 2013				
	5750561	Jul 03, 2012	DP			
	5750561*PED	Jan 03, 2013				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 001	>A> 7727548	Jun 23, 2022	DP U-1062			
	>A> 7727552	Mar 26, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 002	>A> 7727548	Jun 23, 2022	DP U-1062			
	>A> 7727552	Mar 26, 2018	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	>A> 7749532	Dec 19, 2027	DP U-1063			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Dec 08, 2021	DS DP U-930		ODE	Nov 20, 2015
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Mar 04, 2024	DS DP U-930			
<u>EPINEPHRINE - ADRENACCLICK</u>						
N020800 003	5665071	May 27, 2013	DP			
<u>EPINEPHRINE - ADRENACCLICK</u>						
N020800 004	5665071	May 27, 2013	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	6900221	Nov 09, 2020	DS DP U-875	I-624	Apr 16, 2013	
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-1046			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	6900221	Nov 09, 2020	DS DP U-875	I-624	Apr 16, 2013	
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-1046			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	6900221	Nov 09, 2020	DS DP U-875		I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-1046			
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015		DP U-1053	NC	Apr 30, 2013
	5900424	May 04, 2016	DS	U-1053		
	6369085	May 25, 2018	DS DP	U-1053		
	6875872	May 27, 2014	DS			
	6926907	Feb 28, 2023		DP U-1052		
	7411070	May 25, 2018	DS	U-1053		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015		DP U-1053	NC	Apr 30, 2013
	5900424	May 04, 2016	DS	U-1053		
	6369085	May 25, 2018	DS DP	U-1053		
	6875872	May 27, 2014	DS			
	6926907	Feb 28, 2023		DP U-1052		
	7411070	May 25, 2018	DS	U-1053		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 001	7572779	Mar 02, 2024		U-904		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 002	7572779	Mar 02, 2024		U-904		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 003	7572779	Mar 02, 2024		U-904		
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6444673	Feb 14, 2014	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6444673	Feb 14, 2014	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6444673	Feb 14, 2014	DS DP			
<u>ETHINYLEDIESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7615545	Jun 15, 2023		U-1		
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2014	DS DP	U-1049	NP	Apr 20, 2013
	6004973	Jul 12, 2016		DP U-1049	NCE	Mar 30, 2014
	6239124	Aug 11, 2017		U-1049		
	6440990	Sep 24, 2013	DP	U-1049		
	6455518	Jul 29, 2017		U-1049		
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2014	DS DP	U-1049	NP	Apr 20, 2013
	6004973	Jul 12, 2016		DP U-1049	NCE	Mar 30, 2014
	6239124	Aug 11, 2017		U-1049		
	6440990	Sep 24, 2013	DP	U-1049		
	6455518	Jul 29, 2017		U-1049		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2014	DS DP U-1049			
	6004973	Jul 12, 2016	DP U-1049		NP NCE	Apr 20, 2013 Mar 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6455518	Jul 29, 2017	U-1049			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	7612058	Jan 25, 2022	U-1027			
	7612058*PED	Jul 25, 2022				
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	7658944	Dec 09, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	7658944	Dec 09, 2024	DP			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	>A> 7741373	Aug 20, 2027	U-1059			
	>A> 7741374	Aug 20, 2027	U-1061			
	>A> 7741374	Aug 20, 2027	U-1060			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	>A> 7741373	Aug 20, 2027	U-1059			
	>A> 7741374	Aug 20, 2027	U-1061			
	>A> 7741374	Aug 20, 2027	U-1060			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	>A> 7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	>A> 7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	>A> 7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	>A> 7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	>A> 7579019	Jan 31, 2019	U-767			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 002	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 004	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021909 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR</u>						
N021704 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR</u>						
N020786 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 001					NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 002					NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 003					NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 004					NPP	Mar 17, 2013
<u>GATIFLOXACIN - ZYMAXID</u>						
N022548 001	5880283	Dec 05, 2015	DS		NP	May 18, 2013
	5880283*PED	Jun 05, 2016				
	6333045	Aug 20, 2019	DS DP			
	6333045*PED	Feb 20, 2020				
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 001	7700128	Oct 02, 2026	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 002	7700128	Oct 02, 2026	DP			
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387 001	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387 002	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>						
A077157 001				PC	Oct 03, 2010	
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>						
A077157 003				PC	Oct 03, 2010	
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 002	6878703	Nov 19, 2021	U-3	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 003	>A> 6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 004	>A> 6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 005	>A> 6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 001	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 002	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 003	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 002	7718634	May 06, 2023	U-642			
<u>IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE - ADVIL CONGESTION RELIEF</u>						
N022565 001	>A> 5087454	Jul 30, 2010	DP			
<u>IMIQUIMOD - ALDARA</u>						
N020723 001	7696159	Apr 01, 2024	DS U-1048			
	7696159	Apr 01, 2024	DS U-1047			
	7696159*PED	Oct 01, 2024				
<u>IMIQUIMOD - IMIQUIMOD</u>						
A078548 001				PC		Aug 24, 2010
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001				NP		Mar 25, 2013
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	5547930	Sep 28, 2013	DS DP			
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	7713930	Jun 13, 2023	DP			
	7713930*PED	Dec 13, 2023				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 001	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 002	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ITRACONAZOLE - ITRACONAZOLE</u>						
N022484 001	6509038	May 12, 2017	DP U-1054		NP	Apr 29, 2013
	7081255	May 12, 2017	DP U-1054			
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N022382 001	6333044	Dec 25, 2018	DP U-1057			
	7476689	Oct 11, 2012	DP U-1056			
<u>LACOSAMIDE - VIMPAT</u>						
N022255 001	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 001				I-622	Jan 29, 2013	
				NDF	May 29, 2012	
				PED	Nov 29, 2012	
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 002				I-622	Jan 29, 2013	
				NDF	May 29, 2012	
				PED	Nov 29, 2012	
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 003				I-622	Jan 29, 2013	
				NDF	May 29, 2012	
				PED	Nov 29, 2012	
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 004				I-622	Jan 29, 2013	
				NDF	May 29, 2012	
				PED	Nov 29, 2012	
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 005				I-622	Jan 29, 2013	
				NDF	May 29, 2012	
				PED	Nov 29, 2012	
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N022059 001	6713485	Sep 29, 2020	DS DP U-800		I-620	Jan 29, 2013
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N021730 001	>A 5836299	Nov 17, 2015	DP			
<u>LEVETIRACETAM - KEPPTA</u>						
N021872 001				I-563	Mar 19, 2010	
				PED	Sep 19, 2010	
<u>LEVOthyroxine Sodium - TIROSINT</u>						
N021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOthyroxine Sodium - TIROSINT</u>						
N021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOthyroxine Sodium - TIROSINT</u>						
N021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOthyroxine Sodium - TIROSINT</u>						
N021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOthyroxine Sodium - TIROSINT</u>						
N021924 006	7723390	Mar 14, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N022121 001	7723390	Mar 14, 2024	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	6268343	Aug 22, 2017	DS DP U-968		NCE	Jan 25, 2015
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
<u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u>						
N021977 001	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u>						
N021977 002	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u>						
N021977 003	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u>						
N021977 004	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671031	Feb 28, 2023		U-727		
	7678770	Mar 25, 2023		U-842		
	7687466	Feb 24, 2023		DP		
	7700561	Jun 29, 2023		DP		
<u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u>						
N021977 005	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021251 001	5541206	Jul 30, 2013	DS DP U-895		D-124	Apr 27, 2013
	5541206	Jul 30, 2013	DS DP U-348			
	5635523	Jun 03, 2014		U-895		
	5635523	Jun 03, 2014		U-352		
	5886036	Nov 19, 2013	DS DP U-895			
	6037157	Jun 26, 2016		U-895		
	6037157	Jun 26, 2016		U-346		
	6703403	Jun 26, 2016		U-895		
	6703403	Jun 26, 2016		U-257		
	6911214	Nov 28, 2021		DP U-895		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	5886036	Nov 19, 2013	DS DP U-895		D-124	Apr 27, 2013
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	5886036	Nov 19, 2013	DS DP U-895		D-124	Apr 27, 2013
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 001	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 002	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 003	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 001				PC		Oct 03, 2010
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 002				PC		Oct 03, 2010
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 003				PC		Oct 03, 2010
<u>MARAVIROC - SELZENTRY</u>						
N022128 001				NPP		May 28, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
	N022128 002				NPP	May 28, 2013
<u>MESALAMINE - SFROWASA</u>						
	N019618 002	7645801	Jul 24, 2027	DS DP		
<u>METAXALONE - SKELAXIN</u>						
	N013217 003	7714006	Dec 03, 2021		U-1050	
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
	N021842 001	5965584	Jun 19, 2016	DP	U-1055	
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
	N021842 002	5965584	Jun 19, 2016	DP	U-1055	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
	N022044 001	6890898	Feb 02, 2019		U-803	
		6890898	Feb 02, 2019		U-1038	
		6890898	Feb 02, 2019		U-1036	
		7078381	Feb 02, 2019		U-803	
		7078381	Feb 02, 2019		U-1038	
		7078381	Feb 02, 2019		U-1036	
		7125873	Jul 26, 2022	DP	U-803	
		7125873	Jul 26, 2022	DP	U-1038	
		7125873	Jul 26, 2022	DP	U-1036	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
	N022044 002	6890898	Feb 02, 2019		U-803	
		6890898	Feb 02, 2019		U-1038	
		6890898	Feb 02, 2019		U-1036	
		7078381	Feb 02, 2019		U-803	
		7078381	Feb 02, 2019		U-1038	
		7078381	Feb 02, 2019		U-1036	
		7125873	Jul 26, 2022	DP	U-803	
		7125873	Jul 26, 2022	DP	U-1038	
		7125873	Jul 26, 2022	DP	U-1036	
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLINE</u>						
	N021419 001	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLINE</u>						
	N021419 002	7691880	Oct 07, 2024	DP		
<u>MICONAZOLE - ORAVIG</u>						
	N022404 001	6916485	Sep 11, 2022	DP	U-1051	
		7651698	Jan 08, 2026		U-1051	
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
	N020762 001				I-626	May 26, 2013
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
	N022321 001	7682633	Jun 19, 2027		U-443	
		7682634	Jun 19, 2027	DP		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
	N022321 002	7682633	Jun 19, 2027		U-443	
		7682634	Jun 19, 2027	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N021598 001	7671070	Sep 29, 2019	U-709			
	7671070*PED	Mar 29, 2020				
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 005	>A> 5759580	Jun 02, 2015	DP			
	>A> 6545040	Apr 08, 2020	DP U-3			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 004	7659291	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 003	7659291	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 002	7659291	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 005	7659291	Apr 18, 2027	U-1029			
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 001				NPP	Feb 04, 2013	
				PED	Aug 04, 2010	
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 003				NPP	Feb 04, 2013	
				PED	Aug 04, 2010	
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 004				NPP	Feb 04, 2013	
				PED	Aug 04, 2010	
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
N021654 001	>A> 7732488	Jan 30, 2025	DS DP			
<u>OMEPRAZOLE; SODIUM BICARBONATE - OMEPRAZOLE AND SODIUM BICARBONATE</u>						
A078966 001				>A> PC	Dec 28, 2010	
<u>OMEPRAZOLE; SODIUM BICARBONATE - OMEPRAZOLE AND SODIUM BICARBONATE</u>						
A078966 002				>A> PC	Dec 28, 2010	
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001				M-90	Feb 22, 2013	
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002				M-90	Feb 22, 2013	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
	N021087 003				M-90	Feb 22, 2010
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
	N021246 001				M-90	Feb 22, 2013
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 001	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 002	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 003	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 004	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 005	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 006	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 007	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 008	7674799	Mar 30, 2025	DS			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017	DP			
	>A> 7674799	Mar 30, 2025	DP			
	>A> 7674800	Mar 30, 2025	DS			
	>A> 7683072	Mar 30, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017		DP		
	>A> 7674799	Mar 30, 2025		DP		
	>A> 7674800	Mar 30, 2025		DS		
	>A> 7683072	Mar 30, 2025		DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017		DP		
	>A> 7674799	Mar 30, 2025		DP		
	>A> 7674800	Mar 30, 2025		DS		
	>A> 7683072	Mar 30, 2025		DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017		DP		
	>A> 7674799	Mar 30, 2025		DP		
	>A> 7674800	Mar 30, 2025		DS		
	>A> 7683072	Mar 30, 2025		DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017		DP		
	>A> 7674799	Mar 30, 2025		DP		
	>A> 7674800	Mar 30, 2025		DS		
	>A> 7683072	Mar 30, 2025		DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017		DP		
	>A> 7674799	Mar 30, 2025		DP		
	>A> 7674800	Mar 30, 2025		DS		
	>A> 7683072	Mar 30, 2025		DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	>A> 5508042	Apr 16, 2013		U-443		
	>A> 6488963	Jun 24, 2017		DP		
	>A> 7674799	Mar 30, 2025		DP		
	>A> 7674800	Mar 30, 2025		DS		
	>A> 7683072	Mar 30, 2025		DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 001	7276250	Feb 04, 2023		DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 002	7276250	Feb 04, 2023		DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 003	7276250	Feb 04, 2023		DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 004	7276250	Feb 04, 2023		DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 005	7276250	Feb 04, 2023		DP	U-826	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 006	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 007	7276250	Feb 04, 2023	DP U-826			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 001				I-625		Apr 30, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 002				I-625		Apr 30, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 003				I-625		Apr 30, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 001				NCE		Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 002				NCE		Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 003				NCE		Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 004				NCE		Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	7658918	Feb 20, 2028	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	7658918	Feb 20, 2028	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	7658918	Feb 20, 2028	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	7658918	Feb 20, 2028	DP			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N022020 001	7544370	Jun 07, 2026	DP			
	7544370*PED	Dec 07, 2026				
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N020629 001	5866581	Oct 04, 2014	U-501			
	6124304	Oct 04, 2014	U-501			
<u>POLIDOCANOL - ASCLERA</u>						
N021201 001				NCE		Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N021201 002				NCE		Mar 30, 2015
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 001	4886812	Oct 08, 2010	DS DP	I-623		Mar 19, 2013
	7695734	Apr 26, 2028	DP	NDF		Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 002	4886812	Oct 08, 2010	DS DP	I-623		Mar 19, 2013
	7695734	Apr 26, 2028	DP	NDF		Feb 19, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 003	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 004	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 005	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 001					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 002					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 003					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 004					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 005					PC	Jul 03, 2010
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 001	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 002	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 003	6740341	Nov 24, 2019	DP			
<u>PREGABALIN - LYRICA</u>						
N022488 001	5563175	Oct 08, 2013		U-661		I-535
	6001876	Dec 30, 2018		U-819		Jun 21, 2010
	6001876	Dec 30, 2018		U-55		
	6197819	Dec 30, 2018	DS DP			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	7655636	Jun 22, 2019		U-869		
	7655637	Jun 22, 2019	DS DP	U-869		
	7683037	Jun 22, 2019		U-1042		
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 002	7045620	Jun 19, 2024	DS		NP ODE	Mar 24, 2013 Mar 24, 2017
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 005	7718634	May 06, 2023		U-662		
	7718634*PED	Nov 06, 2023				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N022417 001	5541206	Jul 30, 2013	DS DP U-688			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-688			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014	U-688			
	5674882*PED	Apr 07, 2015				
	6037157	Jun 26, 2016	U-688			
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016	U-688			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001					ODE	Nov 05, 2016
<u>ROSVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	7030152	Apr 02, 2018	U-1032	I-621	Feb 08, 2013	
<u>ROSVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	7030152	Apr 02, 2018	U-1032	I-621	Feb 08, 2013	
<u>ROSVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	7030152	Apr 02, 2018	U-1032	I-621	Feb 08, 2013	
<u>ROSVASTATIN CALCIUM - CRESTOR</u>						
N021366 005	7030152	Apr 02, 2018	U-1032	I-621	Feb 08, 2013	
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	6740669	Aug 17, 2020	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	6740669	Aug 17, 2020	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	6740669	Aug 17, 2020	DS DP			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 001	6890898	Feb 02, 2019	U-775			
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1038			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1036			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 002	6890898	Feb 02, 2019	U-775			
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1038			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1036			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 003	6890898	Feb 02, 2019	U-775			
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1038			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1036			
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Mar 07, 2024	U-1028			
<u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N021892 001	7687075	Jun 22, 2028	DS DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 008	5849700	Dec 15, 2015	U-1041	I-572	Oct 31, 2011	
	5849704	Dec 15, 2015	DP U-1041	I-551	Sep 20, 2010	
				I-536	May 31, 2010	
				ODE	May 31, 2014	
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 009	5849700	Dec 15, 2015	U-1041	I-572	Oct 31, 2011	
	5849704	Dec 15, 2015	DP U-1041	I-551	Sep 20, 2010	
				I-536	May 31, 2010	
				ODE	May 31, 2014	
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 010	5849700	Dec 15, 2015	U-1041	I-572	Oct 31, 2011	
	5849704	Dec 15, 2015	DP U-1041	I-551	Sep 20, 2010	
				I-536	May 31, 2010	
				ODE	May 31, 2014	
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	7531623	Jan 01, 2027	DS			
	7700550	May 01, 2021	U-282			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	7531623	Jan 01, 2027	DS			
	7700550	May 01, 2021	U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
	N022088 001				M-91	Apr 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
	N021356 001				NPP	Mar 24, 2013
<u>TERBINAFINE - LAMISIL AT</u>						
N021958 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355	May 18, 2012	DP U-540			
	5856355	May 18, 2012	DP U-504			
	5856355*PED	Nov 18, 2012				
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	>A> 7723361	Mar 01, 2013		U-1058		
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	>A> 7723361	Mar 01, 2013		U-1058		
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	>A> 7723361	Mar 01, 2013		U-1058		
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	>A> 7723361	Mar 01, 2013		U-1058		
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	7642268	Sep 24, 2021	DS DP			
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 001	5559269	Nov 05, 2013		U-318	Y	
	5559269*PED	May 05, 2014				
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 002	5559269	Nov 05, 2013		U-318	Y	
	5559269*PED	May 05, 2014				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 001					PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 002					PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 003					PC	Dec 05, 2010
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
<u>TREPROSTINIL SODIUM - TYVASO</u>						
N022387 001				>A> ODE		Jul 30, 2016
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N022437 001	5776885	Jul 07, 2015	DP		NP	Mar 10, 2013
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 001	7696206	Oct 31, 2018	DS DP	U-533		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 002	7696206	Oct 31, 2018	DS DP U-533			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 003	7696206	Oct 31, 2018	DS DP U-533			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 004	7696206	Oct 31, 2018	DS DP U-533			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001	7265119	Aug 03, 2022	DS DP U-56			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002	7265119	Aug 03, 2022	DS DP U-56			
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N022575 001					NCE	Feb 26, 2015
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N022575 002					NCE	Feb 26, 2015
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	7652069	Mar 04, 2023	DS			
	>A> 7732490	Mar 04, 2023	U-892			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor.
They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2010 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>